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The mitochondrion is the cell’s “power plant” as it produces most of the energy in 
cells through oxidative phosphorylation. Electrons are passed through a series of 
respiratory enzyme complexes located in the inner mitochondrial membrane. The energy 
released by this electron transfer is used to pump protons across the membrane. This 
results in the formation of an electrochemical gradient, which enables adenosine 5-
triphosphate (ATP) synthase to synthesize the energy carrier ATP (Figure 1).  
A series of four enzyme complexes forms the electron-transport chain. Electrons 
are passed through these complexes from lower to higher standard reduction potentials. 
Complex I (NADH:Ubiquinone Reductase) catalyzes the oxidation of nicotinamide 
adenine dinucleotide (NADH) by Coenzyme Q (CoQ). Complex II 
(Succinate:Ubiquinone Reductase) catalyzes the oxidation of flavin adenine dinucleotide 
(FADH2) by CoQ. Because this redox reaction does not release sufficient free energy to 
synthesize ATP, Complex II functions only to extract the electrons from FADH2 and 
transfer them into the electron-transport chain. CoQ then carries electrons to Complex III 
(Ubiquinol:Cytochrome c Reductase or bc1 complex), which catalyzes oxidation of 
reduced CoQ by cytochrome c. Complex IV (Cytochrome c Oxidase) catalyzes the 
oxidation of reduced cytochrome c by O2, the terminal electron acceptor of the electron-
transport process (Figure 2). The free energy released by electron transport is utilized by 
Complex V (ATP synthase) to synthesize ATP. Peter Mitchell first proposed the 
chemiosmotic theory (the general mechanistic principle of oxidative and 








Figure 1. Mitochondrial electron-transport chain
synthesis in mitochondria. It has become a paradigm in the intellectual framework of 
bioenergetics since the mid-1970. 
During the past 20 years, study in mitochondrial bioenergetics has shifted from 
experiments with crude organelle preparations to direct molecular approaches. Atomic 
resolution structures are now available for several complexes of the electron transport 
chain. They are cytochrome bc1 (1,2), cytochrome c oxidase (3,4), and F1 of ATP 
synthase (5) from bovine, F1c10 complex from Saccharomyces cerevisiae (6), 
succinate:ubiquinone oxidoreductase from Escherichia coli (E. coli) (7), and fumarate 
reductase, which some believe is the homologous enzyme of Complex II, from E. coli (8) 
and Wolinella succinogenes (9). 
The structural information of electron transfer complexes not only has 
substantiated earlier biophysical and biochemical experimental data about enzyme 
mechanisms, but also stimulated discussions about possible alternative mechanisms. For 
example, the crystal structure of the F1-ATPase reveals the intrinsic asymmetry of the 
enzyme, and supports the proposal of Boyer (10) that the three active sites within the F1 
head function in a rotating manner. The histidine cycle hypothesis of cytochrome c 
oxidase was favored before the structure information was available. It proposes that two 
protons are simultaneously carried through the barrier by a moving histidine (11). Recent 
crystallographic studies refute the histidine cycle hypothesis, as the metal coordination 
does not appear to change upon reduction of the enzyme. Based on the crystallographic 
data, two putative channels, D (D91) and K (K319) channels, for delivery of protons to 
the dioxygen reduction site and for pumping of protons across the membrane were 
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proposed (4). This led to a new search for a possible proton-pumping mechanism in 
cytochrome c oxidase. The mechanism remains unclear, and the debate continues (12,13). 
Complex I, NADH:Ubiquinone Oxidoreductase 
 This complex is the entry point for electrons from NADH into the respiratory 
chain of mitochondria. It is the largest, most complicated, and least understood among the 
complexes. It catalyzes the electron transfer from NADH through a series of enzyme 
bound redox centers (flavin mononucleotide (FMN) and Fe-S clusters) to ubiquinone, 
which is reduced to ubiquinol. An electrochemical proton potential gradient across the 
membrane of the mitochondrion is formed by converting the redox energy during this 
process. It is generally considered that for every two electrons that pass through the 
enzyme, four protons are translocated out of the mitochondrial matrix (14). 
Bovine complex I contains at least 45 different subunits in an unknown 
stoichiometry and has a molecular weight over 1,000 kilo Daltons (kDa). There are at 
least 35 subunits in Neurospora crassa, another eukaryote that has been extensively 
studied, and with a total molecular weight over 700 kDa (15-17). Even in Paracoccus 
denitrificans, a Gram-negative soil bacterium, this complex contains at least 14 subunits, 
which is considered the minimum requirement of this complex (18).  
In bovine complex I, there are seven hydrophobic intrinsic membrane subunits, 
known as ND1-ND6 and ND4L (19). They are encoded by the mitochondrial genome, 
and have been sequenced in a wide range of eukaryotes. These include mammals (20-22), 
birds (23), fish (24), insects (25,26), amphibians (27), invertebrates including sea urchins 
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(28), nematode worms (29) and brine shrimps (30), protozoans (31), algae (32), and fungi 
(33-35). Homologues of these subunits are also encoded in the chloroplast genomes of 
higher plants (36,37). The homologues of part or all of the mitochondrial genes among 
these species prove the presence of complex I in a wide variety of species. The yeast 
Saccharomyces cerevisiae has no ND genes in its mitochondrial DNA and is a notable 
exception. The rest of the constituent polypeptides of this complex, thirty-five so far, are 
nuclear gene products that are imported into the organelle from the cytoplasm of the cell 
(38). The monomeric enzyme complex from bovine heart mitochondria contains one 
FMN, at least six different iron-sulfur centers (two [2Fe-2S], N1a and N1b; four [4Fe-
4S], N2 to N5), and at least three bound quinol molecules (one ubiquinone, and two EPR-
detectable semiquinone species) (16,39,40). By using an azido-ubiquinone derivative, our 
group rececntly identified the ubiquinone-binding site in E. coli complex I, which locates 
in the helix 4 of NuoM subunit (41).  A comparison of mammalian and bacterial complex 
I shows the presence of 32 strictly conserved cysteine residues, which allows the binding 
of eight iron-sulfur centers (42). 
There are several ways to subfractionate the bovine complex I (43-45). The most 
commonly used is to treat the isolated enzyme with the chaotropic anion, perchlorate (see 
Figure 2). This process separates the complex into two fractions, a soluble fraction and a 
precipitate hydrophobic protein fraction, HP. The soluble fraction can be further resolved 
into two parts, a flavoprotein containing fraction (FP) and an iron-protein containing 
fragment (IP). The FP fraction contains one molecule of each of the 51 ([4Fe-4S] and 
FMN), 24 ([2Fe-2S]), and 10 kDa protein subunits, one molecule of FMN and six atoms 
of bound iron (46). As found in complex I (47,48), it has the same kinetic parameters of 
6
NADH and NAD+ binding, and ferricyanide and other artificial substrates can act as 
electron acceptors. The 51 kDa subunit has been identified as the NADH-binding site by 
photoaffinity labeling (49). In the fraction IP, its flavin content is low, and it contains 48 
nmol Fe mg-1 of protein, which corresponds to 9-10 of the iron atoms in complex I (50). 
The IP fragment is not a homogeneous stoichiometric complex, and its polypeptides 
composition seems to differ from one to the other preparations. But it appears the 75, 49, 
30, 18, 15 and 13 kDa subunits are considered invariant (51).  
The HP fraction is the precipitate from the perchlorate treatment with all the rest 
of the subunits, and it doesn’t show any structural integrity. It contains not only the 
hydrophobic components of complex I, for example, ND1 (51), but also globular water-
soluble subunits of complex I, for example, PSST ((38), also see Figure 2). 
Another common way to disrupt the bovine complex I is to use detergent (N,N-
dimethyldodecylamine N-oxide) treatment to split the enzyme into two subcomplexes, 
named Iα and Iβ (52). Iα contains 22 subunits, and represents the majority of the 
extrinsic membrane domain of complex I. It has all of the subunits of IP and FP fractions, 
as well as many other subunits that are indicated to be globular by their sequences. 
However, it also contains some of the hydrophobic subunits, ND2, MLRQ, B9, MWFE, 
and the 42 kDa subunits. Subcomplex Iα can transfer electrons from NADH to 
ferricyanide or ubiquinone-I, and contains all of the iron-sulfur clusters that have been 
detected by electron paramagnetic resonance (EPR) spectroscopy in intact complex I. 
Subcomplex Iβ consists of about 13 different polypeptides. They include the hydrophobic 





Figure 2. Subfractionation of bovine Complex I. 
8
show any known redox centers (52), and no biochemical functions have been detected 
(38). Table I shows all of the nuclear-coded subunits in bovine complex I and their 
properties (modified from (38)). 
Photoaffinity analogues of NAD+ react with the 51 kDa subunit in the FP 
fragment (49). Therefore, it is believed that the NADH binding site is within the 51 kDa 
subunit. By sequence comparison with other NADH-binding sites of known structure, 
Walker suggested a possible location of this binding site in the 51 kDa subunit (38). But 
the exact location of the NADH binding site remains unknown. FMN, which is usually 
considered as the most likely immediate oxidant of NADH, is also thought to bind with 
the 51 kDa subunit (38). The standard reduction potential of FMN is between those of 
NADH and the most electronegative of the EPR visible iron-sulfur clusters. It can take up 
two electrons at a time and release one at a time to the one electron acceptor Fe-S cluster, 
and still maintain a stable structure. Since the substrate NADH is bound at the 51 kDa 
subunit, one may predict that the FMN might be bound to the same polypeptide. There is 
no evidence that shows the other two subunits of the FP fraction, 24 kDa and 10 kDa, 
bind with FMN. There was a prediction, also suggested by Walker, of the possible 
binding site for FMN in the 51 kDa subunit, but the exact location will be revealed once 
the structure information becomes available (38). 
The Iα subcomplex of complex I, which includes both FP and IP fragments, 
contains all of the iron-sulfur clusters that have been detected by EPR spectroscopy in 
intact complex I. In an effort to localize the subunits that host these Fe-S clusters of 
bovine complex I, EPR spectra were determined for the FP and IP fragments, and simpler 
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fragments were derived from them by further purification. Thus, clusters N-1b and N-3 
were localized in the 24 kDa subunit and 51 kDa subunit, respectively (53). The other 
clusters were found or predicted to be housed in 75 kDa, TYKY (23 kDa), and PSST (20 
kDa) subunits, as show in Table I (15,37,54,55). 
Due to the extreme structural complexity, the difficulty of applying optical 
spectroscopy to analyze the redox state of intrinsic chromophores within the membrane, 
and the absence of inhibitors that block the pathway at specific intermediate sites, the 
study of the electron pathway of complex I is extremely difficult (38,56). However, the 
L-shape (57), two arms structure with a water soluble peripheral part that contains all 
known prosthetic groups and a membrane part that carries the binding site for ubiquinone 
provides a framework to constrain the proton-translocating machinery. 
The FP fragment of bovine complex I, also called NADH dehydrogenase, is 
considered as the entry point of electron translocation of this complex.  Its FMN and 
NADH binding ability, the presence of Fe-S clusters N-1b and N-3, and simplicity to 
prepare in comparison with the whole enzyme complex, make it an attractive candidate to 
be the first fully understood subcomplex of this complicated complex. Its structural 
information through crystallography will greatly facilitate the studies of the electron 
transport pathway within complex I, and shed light on the involvement of mitochondria 
in aging and cell death, Parkinson’s disease and Huntington’s disease, which are related 





by gel from amino
(kDa) sequence acids
75 kDa (IP) 75 76960.2 704
51 kD (FP) 51 48416.1 444
49 kDa (IP) 49 49174.4 430
42 kDa 42 36692.8 320
39 kDa 39 39115.1 345
30 kDa (IP) 30 26431.8 228
24 kDa (FP) 24 23814.4 217
B22 22 21700.6 178
TYKY 23 20195.9 176
PDSW 22 20833.6 175
PSST 20 20077.5 178
PGIV 19 19959.9 171
ASHI 19 18737 158
SGDH 16 16726.3 143
B18 18 16476.5 136
18 kDa (IP) 18 15337.2 133
B17 16.5 15434.9 127
B15 15 15095.1 128
B14 14 14964.3 127
B13 13 13226.4 115
15 kDa (IP) 15 12536.4 105
B8 8 10990.6 98
B12 12 11009.4 97
13 kDa (IP) 13 10535.7 96
SDAP 8 10109.5 88
B9 9 9217.7 83
MLRQ 9 9324.7 82
10 kDa (FP) 10 8437.3 75
AGGG 7.9 8493.3 72
MWFE 7.5 8135.4 70
MNLL 7 6966.1 57
KFYI 6 5828.7 49
B17.2 17.2 17131.6 145





[4Fe-4S] (N-1a); [4Fe-4S] (?); [2Fe-2S] 
















Complex II, Succinate–Ubiquinone Oxidoreductase 
Succinate-ubiquinone oxidoreductase (SQR), which catalyzes electron transfer 
from succinate to ubiquinone (Q), has been isolated and characterized (58-60). The 
reductase is composed of two parts: soluble succinate dehydrogenase and a membrane 
anchoring protein fraction. Purified reductase has five protein subunits in a high 
resolution sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
system with apparent molecular weights of 70, 27, 15, 13, and 11 kDa (61). The two 
largest subunits are succinate dehydrogenase and the three smaller ones comprise the 
membrane anchoring protein fraction. The isolated complex contains six prosthetic 
groups: one FAD, three iron–sulfur clusters ([2Fe–2S], [3Fe–4S], and [4Fe–4S]), 
cytochrome b-560, and Q. The FAD is covalently bound to the 70 kDa subunit (Fp) and 
all three iron–sulfur clusters are in the 27 kDa subunit (Ip) of succinate dehydrogenase 
(62,63). Cytochrome b-560 and Q are found in the membrane anchoring protein fraction 
(64). While studies of succinate dehydrogenase have been extensive and a wealth of 
information has been obtained (62), knowledge of the membrane anchoring protein 
fraction is relatively limited (65). 
The membrane anchoring protein fraction has been isolated in several laboratories 
under different names, such as CII3, 4 (66), cytochrome b560 fraction (67), or QPs (68). 
The term, QPs (Quinone-binding Protein in SQR), was named by our group (Table II). 
QPs provides membrane anchoring for succinate dehydrogenase and is responsible for 
the Q-binding in succinate–ubiquinone reductase. The ubisemiquinone radicals, which do 
not show power saturation, even at 200 mW, are detected in intact and reconstituted 
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Table II Subunit composition of bovine heart SQR 
 
Molecular 





70 Flavin Protein (FP) His-FAD (5.8 nmol/mg) -79 









15 Q-binding Protein (QPs1)
13 Q-binding Protein (QPs2)











succinate–ubiquinone reductases in the presence of exogenous Q (69). When quinone 
derivatives are used as the electron acceptor for succinate–ubiquinone reductase, a 5 
carbon side chain is required for maximum activity (70) and the methyl group at the 5-
position is less important than are the methoxy groups at the 2- and 3-positions (71). 
Replacing the 5-methyl group with hydrogen causes a slight increase in activity. 
However, replacing one or both of the 2- and 3-methoxy groups with a methyl 
completely abolishes electron-acceptor activity.  
When succinate–ubiquinone reductase is subjected to photoaffinity labeling with 
an [3H]azido-Q derivative, most of the radioactivity was found in the QPs1 subunit, 
indicating that QPs1 is involved in Q-binding (61). The Q-binding domain in QPs1, using 
a structure for QPs1 based on the deduced amino acid sequence (72,73), is located in the 
stretch connecting transmembrane helices 2 and 3, which extrudes from the surface of the 
M side of the mitochondrial inner membrane (61) (Figure 3).  
In addition to participating in Q-binding, QPs1 is believed to be cytochrome b560. 
The involvement of cytochrome b560 in catalysis by succinate–ubiquinone reductase is 
controversial. The presence of substoichiometric amounts of cytochrome b560, with 
respect to FAD, in isolated beef succinate–cytochrome c and succinate–ubiquinone 
reductases, together with its non-reducibility by succinate has led some investigators to 
rule out a catalytic function for cytochrome b560. On the other hand, it has been proposed 
that cytochrome b560 functions as a mediator between low potential F1/F· and Q/Q· 
couples in a dual pathway model (74) of electron flow through cardiac Complex II. 




Figure 3. Proposed structure of QPs1. Bold line indicates the tryptic peptide involved in 
Q-binding of QPs1. 
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succinate dehydrogenase to QPs as indicated by the restoration of its absorption 
properties, redox potential, and EPR characteristics, upon reconstitution of succinate–
ubiquinone reductase from QPs and succinate dehydrogenase (64). 
The ligands of cytochrome b560 in E. coli and beef succinate–ubiquinone 
reductases have been identified as bis-histidine (75,76). H42 and H98 of QPs1 are 
thought to be involved in heme ligation of cytochrome b560 in the beef enzyme (72) 
because these two histidines are conserved in sdh C peptides of E. coli and Bacillus 
subtilis and are located on the matrix side of the membrane. However, the report of 
Nakamura et al. (77), using a gene deletion approach, indicates that both sdhC and sdhD 
peptides of the E. coli enzyme are required for heme ligation of cytochrome b556. Precise 
localization of these bis-histidine ligands will facilitate our understanding of electron 
transfer in this segment of the mitochondrial respiratory chain. 
The 3-D structure of E. coli SQR was reported in 2003 (7). Comparison of the 
transmembrane domain subunits (SdhC and SdhD) between E. coli SQR and E. coli and 
W. succinogenes fumarate reductase (QFR) shows some major differences (Figure 4): 1) 
number of subunits. E. coli SQR and QFR have two subunits (three transmembrane 
helices for each), whereas W. succinogenes QFR has only one subunit, with five 
transmembrane helices; 2) number of heme b molecules. E. coli SQR has only one heme 
b; however, W. succinogenes QFR has two heme b molecules and E. coli QFR has none. 
The histidine ligands for heme b were identified as H84 of SdhC, and H71 of SdhD in 








Figure 4. Comparison of the transmembrane domain structures of (A) E. coli SQR, (B) 
E. coli QFR, and (C) W. succinogenes QFR. All three are viewed parallel to the 
membrane from the same direction. SdhC and SdhD subunits are shown in green and 
blue, respectively. The equivalent subunits in E. coli QFR are shown in the same colors. 
W. succinogenes QFR has a single transmembrane subunit. Ubiquinone and menaquinone 
are shown in brownish yellow in (A) and (B). Heme b and cardiolipin are shown in 
purple and gray, respectively. Gray shading represents the position of the membrane (7). 




Complex III, Ubiquinol:Cytochrome c Oxidoreductase 
Ubiquinol:cytochrome c oxidoreductase catalyzes the transfer of electrons from 
ubiquinol to cytochrome c, both oxidation of ubiquinol (QH2) and reduction of 
ubiquinone (Q) occur during the reaction cycle as part of the proton-translocating 
apparatus (78).  
Bovine mitochondrial cytochrome bc1 contains 11 protein subunits with four redox 
prosthetic groups: cytochromes b566 (bL) and b562 (bH) cytochrome c1, and a high-
potential iron–sulfur cluster [(2Fe–2S)]. The three (subunits III, IV, and V), which house 
b-type cytochromes, cytochrome c1, and the iron–sulfur cluster, respectively, are 
essential subunits, while the eight (subunits I, II, VI–XI) containing no redox prosthetic 
groups are termed supernumerary subunits. The complex consists of 2165 amino acid 
residues with a total molecular mass of 248 kDa, not including approximately forty 
molecules of bound phospholipids (79). 
The three-dimensional (3-D) structure of bovine mitochondrial bc1 complex was 
first available in 1997 by collaboration between our group and Dr. Deisenhofer’s group. 
The structure information not only established the location of the redox centers and 
inhibitor binding sites but also suggested some unexpected features of the complex, 
which are: movement of the head domain of the iron-sulfur protein (ISP) during bc1 
catalysis (1,2,80,81); close interaction between two symmetrically related monomers (1); 
and inhibition of the mitochondrial-processing peptidase (MPP) activity by the binding of 
subunit IX at the active site of MPP, located in interface of the subunits I and II (82). 
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As shown in Figure 5 (83), the cytochrome bc1 complex can be divided into three 
regions: matrix, transmembrane helix, and intermembrane space. The enzyme projects 75 
Å into the matrix space, spans 42 Å within the inner mitochondrial membrane, and 
extends 38 Å into the intermembrane space. The core 1 and core 2 subunits, along with 
subunits VI and IX, position entirely in the matrix space. Cytochrome b, cytochrome c1, 
the iron-sulfur protein, and subunits VII, X, and XI span the membrane, while subunit 
VIII lies solely in the intermembrane space. 
 The transmembrane helix region consists of 13 helices in each monomer, eight 
from cytochrome b (A-H), and the remaining five belonging to cytochrome c1, ISP, and 
subunits VII, X, and XI. Four helixes (A-D) of cytochrome b form a bundle, which both 
heme bL and bH are bound to. Heme bL is liganded by residues H83 and H182 from 
helices B and D, respectively; while heme bH is liganded by H97 and H196 from helices 
B and D. The Qi site of the protein has been defined by structures of the enzyme in the 
presence and absence of the Qi site inhibitor antimycin. Residues from helices A, D, and 
E, and a short helix near the N terminus of the peptide chain form the binding pocket. 
The electron density for antimycin suggests that this inhibitor binds within 4 Å of heme 
bH. By analogy, ubiquinone should bind in a similar fashion at this site. The Qo site of the 
protein positions within cytochrome b near the iron-sulfur protein. It consists mainly of 
residues from helix C, helix F, the loop region connecting helices C and D, and the loop 
connecting helices E and F (42). 
 Cytochrome c1 consists of an extramembranous domain in the intermembrane 
space along with a single transmembrane helix. Heme c1 is liganded with residues C37 
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Figure 5. Structural model of the dimeric bovine mitochondrial cytochrome bc1 
complex. The polypeptides are drawn as ribbons and heme moieties as ball-and-stick 
models. The top of the diagram is in the mitochondrial intermembrane space; the 
bottom is in the mitochondrial matrix space. Figure is taken from reference 83. 
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and C40. The carboxy group of one of the propionates of heme c1 forms a salt bridge with 
R120, while the other propionate of the heme extends toward the iron-sulfur protein. A 
methyl group on the porphyrin ring is solvent-exposed, likely near the binding site for 
cytochrome c (42,83).  
 The iron-sulfur protein (ISP) contains a transmembrane helix and a hydrophilic 
domain in the intermembrane space. ISP extends across the interface between the two 
monomers, with the transmembrane helix in one monomer and the extramembranous 
domain within the other. This intertwining structure of the two monomers implies that the 
functional enzyme complex exists as a dimer. In ISP, the [2Fe-2S] cluster positions near 
the edge of the extramembranous domain, bound by C139, H141, C158, and H161. A 
comparison of reported crystal structures has shown that the position of [2Fe-2S] changes 
during the binding of different Qo site inhibitors (1,2,81), suggesting that domain 
movement is part of the reaction mechanism of the enzyme. Further more, molecular 
genetic manipulation of the flexibility of the ISP neck region in the bacterial cytochrome 
bc1 complex has shown greatly reduced electron transfer activity with decreased 
flexibility of the neck region (84,85).  
 Binding of inhibitors at the Qo site has revealed two overlapping substrate binding 
pockets. In the presence of inhibitor stigmatellin, the iron-sulfur cluster is in contact with 
the Qo site (78,84). The electron density for stigmatellin suggests a possible hydrogen 
bond with H161 of the iron-sulfur protein. The distance between the stigmatellin and 
heme bL is 12 Å. In the presence of inhibitors myxothiazole or methoxyacrylate-stilbene 
reveal that the distance from the ring structures of these two inhibitors are approximately 
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5.5 Å toward heme bL, relative to the position of stigmatellin (86). Also, the iron-sulfur 
cluster was oriented toward the c1 heme in these crystals and was not interacting directly 
with the inhibitors. In the presence of inhibitor 5-undecyl-6-hydroxy-4,7-
dioxobenzothiazol (UHDBT), it appears to bind in a position intermediate between those 
of stigmatellin and myxothiazole, with a weak interaction between the inhibitor and the 
ISP (81). 
 In 1976, Mitchell proposed the Q-cycle mechanism for turnover of cytochrome 
bc1 to explain the phenomenon of oxidant-induced reduction. The reduction level of the b 
hemes in anaerobic, succinate-reduced mitochondria increased upon exposure of the 
mitochondria to dioxygen, particularly in the presence of the inhibitor antimycin (87). As 
shown in Figure 6, the key features of this mechanism for electron transfer and proton 
translocation are the bifurcation of quinol oxidation at the Qo site and quinone reduction 
at a separate Qi site (87,88). After one full reaction cycle, two molecules of ubiquinol are 
oxidized, with the associated release of four protons to the cytoplasmic side of the 
membrane, one molecule of ubiquinone is reduced, coupled to the uptake of two protons 
from the matrix space, and two molecules of cytochrome c are reduced. Overall, four 
protons are released for every two molecules of cytochrome c reduced, giving a 2H+/1e- 
proton translocation stoichiometry (Equation 1). 
 
(1) 
 The most important point of this mechanism is that the branched electron transfer 





Figure 6. Schematic diagram of the Q-cycle mechanism of cytochrome bc1. Thick arrows 
denote substrate transformation or movement. Thin arrows denote electron transfer. Q: 








thermodynamically favored reaction is the transfer of both electrons from ubiquinol 
through ISP to cytochrome c, bypassing the b hemes altogether. Thus, the key to proton 
pumping in this enzyme is directing the second electron from the oxidation of ubiquinol 
into cytochrome b instead of the iron-sulfur cluster. There are two hypotheses for this 
scheme. First, the mobile ISP extramembrane domain, reduced by the first electron from 
quinol, can only donate the electron to cytochrome c1 after the second electron from 
semiquinone reduces heme bL due to a 31 Å distance between ISP and cytochrome c1 
(89). This is in accord with single-turnover experiments of quinol with cytochrome bc1, 
in which heme b reduction is more rapid than that of heme c1 (90-92).  The electron 
transfer from semiquinone to heme bL is faster than the diffusion motion of the ISP which 
is necessary for the cytochrome c1 reduction. 
 Second, after the reoxidation of ISP, which is close to heme c1 at the time, is 
unable to return to its original position, to be reduced, until the second electron from 
semiquinone reduces heme bL (93).  The fact that there are different sites for inhibitor 
binding in the Qo site seems to support this hypothesis. There are two possible binding 
modes for the quinol oxidation, one is specific for quinol, which is similar to that 
observed for stigmatellin, while the other is for semiquinone, which is similar to that 
observed for myxathiazole (42). 
 Both hypotheses lead to a speculation that the change of the quinol-binding site to 
a semiquinone binding site, along with the reduction of heme bL, result in a 
conformational change in cytochrome b which facilitates the electron transfer between 
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ISP and cytochrome c1 by allowing ISP to move close to heme c1 (89,93). However, the 
lack of detectable ubisemiquinone during catalysis does not support this hypothesis (94). 
 In 1998, Yu et al. proposed that the electron donor for the ISP is a quinol heme bL 
complex, rather than quinol itself (89). Once the first electron of quinol within the 
complex is transfered to ISP, the second electron immediately transfers to heme bL and 
then to heme bH. Thus, no semiquinone is generated. The structure information revealing 
the close proximity of the two bL from each of the monomer suggests the possibility that 
this might facilitate the transfer of the second electron to heme bL. Thus the second 
electron of quinol may reach heme bH or Q at the Qi site around the same time as the first 
electron reaches heme c1. While the exact nature of quinol binding in the Qo site is 
unknown, it is the major remaining issue in understanding the fundamental electron 
transfer and proton translocation process in this enzyme. 
 Structural evidence of quinone binding at the Qi site (1) is in line with the Q-cycle 
mechanism. Quinone is closely bound to heme bH, within 5 Å of the edge of the heme 
tetrapyrrole, allowing a rapid electron transfer between Q and heme bH and vice versa. 
An aspartate residue (D228), which is very close to one of the carbonyl groups of 
quinone, may play a role in protonations, after quinone is reduced (83). The potential 
energy of the cytochrome b increases due to the introduction of a negative charge at the 
Qi site, which results from electron transfer from semiquinone to heme bH and quinone at 
the Qi site. Compensation of the negative charge through proton uptake, and reduction of 
quinone or semiquinone at the Qi site complete the electron transfer through the enzyme. 
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 The crystal structures of cytochrome bc1 have provided not only a structural basis 
for the Q-cycle mechnism, but also insight into the details of the branched electron 
transfer mechanism. As a result of substrate binding, electrostatic interactions, and 
intrinsic domain movements, significant changes in the structure of the protein take place 
during the reaction cycle. The mechanism of cytochrome bc1 can serve as a basis for 
understanding the requirements for proton pumping on a molecular level. 
 Because of the difficulty of following the reduction of ISP optically and the 
relative long mixing dead time of conventional stopped-flow apparatus, direct evidence 
of the early involvement of ISP in ubiquinol oxidation is not available. To be able to 
observe the reduction of ISP and its relation to heme b reduction by quinol at the Qo site 
will greatly facilitate the study of the electron transfer in complex III. 
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 The QPs1 subunit of bovine heart mitochondrial succinate–ubiquinone reductase 
was over-expressed in Escherichia coli DH5α cells as a glutathione S-transferase fusion 
protein (GST–QPs1) using the expression vector, pGEX/QPs1. QPs1 is released from the 
fusion protein by proteolytic cleavage with thrombin. Isolated recombinant QPs1 shows 
one protein band in SDS-polyacrylamide gel electrophoresis corresponding to the subunit 
III of mitochondrial succinate–ubiquinone reductase. Although isolated recombinant 
QPs1 is dispersed in 0.01% dodecyl maltoside, it is in a highly aggregated form, with an 
apparent molecular mass of over 1 million. Recombinant QPs1 contains little cytochrome 
b560 heme. However, addition of hemin chloride reconstitutes the spectral characteristics 
of cytochrome b560. Reconstituted cytochrome b560 in recombinant QPs1 shows an EPR 
signal at g=2.91.  Histidine residues at positions 98 and 120 are responsible for heme 
ligation because the H98N or H120N-reconstituted QPs1 fail to restore cytochrome b560 






 A better understanding the structural and functional relationship of SQR, 
especially of the amino acid residues involved in Q-binding, succinate dehydrogenase 
docking, and heme b560 ligation, requires functionally active QPs subunits. Three 
subunits, denoted as QPs1, QPs2, and QPs3, with apparent molecular masses of 15, 13 
and 11 kDa, respectively, are found in the purified, reconstitutively active QPs.  QPs1 has 
been thought as cytochrome b560.  Thus it is necessary to obtain purified QPs1 for heme-
ligating studies.  There are two ways to obtain purified QPs1: one is by biochemical 
resolution of QPs; the other is by gene expression to generate recombinant QPs1 protein.  
The availability of the cDNA for QPs1 in our laboratory together with our past 
experience in over-expressing the subunit VII and subunit IV of the cytochrome bc1 
complexes from beef heart mitochondria and Rhodobacter sphaeroides encouraged us to 
obtain purfied QPs1 by the gene expression approach.  The pGEX expression system was 
used because it allows one step purification of recombinant fusion protein with 
glutathione-agarose gel (1).   Herein we report the construction of the expression vector, 
pGEX/QPs1, growth conditions for over-expression of the active soluble form of GST-
QPs1 fusion protein in E. coli DH5a and properties of recombinant QPs1. The heme b-
560 ligating property of recombinant QPs1 is established by its ability to restore the 
spectra properties of cytochrome b560 upon addition of hemin chloride. The amino acid 








 Restriction endonucleases, T4 DNA ligase, T4 DNA polymerase and T4 
polynucleotide kinase were obtained from either Promega Corporation or Bethesda 
Research Laboratories. DNase I (Type IV), RNase A, isopropyl-β-D-
thiogalactopyranoside (IPTG), gelatin, ampicillin, tetracycline, D-aminolevulinic acid, 
ferrous sulfate, hemin chloride, sorbitol, betaine, glutathione (reduced form), glutathione–
agarose beads, thrombin, leupeptin, 2,6-dichlorophenol indophenol (DCPIP) and 
phenylmethylsulfonylfloride (PMSF) were from Sigma. Nitrocellulose membrane was 
from MSI. Agarose, acrylamide, bis-acrylamide, Horseradish Peroxidase (HRP) color 
development reagents 4CN, and protein A horseradish peroxidase conjugate were from 
Bio-Rad. LB agar, LB broth base, Select Peptone-140, and Select Yeast Extract were 
from GIBCO BRL. Oligonucleotides were synthesized by the DNA/Protein Core Facility 
at Oklahoma State University. Antibodies against QPs1 were generated in rabbits and 
purified by the method previously reported (2). Other chemicals were obtained 
commercially in the highest purity available.  
Bacterial Strains and Plasmids 
 E. coli JM109 [recA1, endA1, gyrA96, thi-, hsdR17 (r-k, m-k), supE44, relA1, λ-, 
∆(lac, pro), F', traD36, proAB lacIqZ ∆M15] was used as host for pSelect (Promega), 
and pGEX-2TH (Pharmacia) plasmids. E. coli DH5α[F-, φ80d, lacΖ∆Μ15, endA1, 
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recA1, hsdR17 (r-k, m+k), supE44, thi-1, λ-, gyrA96, ∆(lacZYA-argF), U169] was used as 
host for pGEX-2TH/QPs1. E. coli strains were grown in LB medium (3). E. coli strain 
INV F'[–F’, endA1, recA1, hsdR17, (rk-, mk+), supE44, thi-1, gyrA96, relA1, φ80d, 
lacΖ∆Μ15, ∆(lacZYA-argF), U169, λ-] was used as host for pCR2.1 vector (Invitrogen) 
and single strand DNA preparation. When necessary, ampicillin (100 µg/ml) or 
tetracycline (15 µg/ml) was added. 
DNA Manipulation and DNA Sequencing 
 Restriction enzyme digestion, large-scale isolation and minipreparation of 
plasmid DNA, were performed according to reported methods (3). DNA sequencing was 
performed with an Applied Biosystems model 373 automatic DNA sequencer at the 
Recombinant DNA/Protein Resource Facility at Oklahoma State University. 
Construction of E. coli Strains Expressing Wild-type and Mutant QPs1  
 QPs1 DNA mutations were generated by site-directed mutagenesis using the 
Altered SitesTM Mutagenesis system from Promega. A 432 bp BamHI–HindIII fragment 
from pSelectampr/QPs1B∆BH was cloned into BamHI and HindIII sites of pGEX-2TH to 
generate pGEX/QPs1 expression plasmid. The single-stranded pSelect/QPs1 was used as 
the template in the mutagenesis reactions. The mutagenic oligonucleotides used were as 
follows:   
H26D 5’-TTGTCTCCCGATATCAGCAT; H42D 5’-GTCCATTTGCGACCGTGGCAC;   
H70D 5’-CTTTGAGTCTGATTTGGAATT; H85D 5’-AGCACTGATCGACACAGCCAA; 
H98D 5’-TCTCATGTATGACACCTGGAA; H105D 5’-TGGGATCCGAGACTTGATGTG; 
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H120D 5’-TTTCCCAGCTAGACCAGTCTG;                               
H26N 5’-TTGTCTCCCAATATCAGC; H42N 5’-GTCCATTTGCAACCGTGGCACTGGT; 
H70N 5’-CTTTGAGTCTAATTTGGA; H85N 5’-AGCACTGATCAACACAGCC;   
H98N 5’-CTCATGTATAACACCTGG; H105N 5’-GGGATTCGAAACTTGATG;     
H120N 5’-TCCCAGCTAAACCAGTCT. 
 The single mutant of QPs1: H26D, H42D, H70D, H85D, H98D, H105D, H120D, 
H26N, H42N, H70N, H85N, H98N, H105N, and H120N were constructed by using each 
of these oligonucleotides, in combination with an ampicillin repair oligonucleotide, and 
annealed to the single-stranded pSELECT/QPs1. The double mutants, QPs1 (H26D & 
H69D), QPs1 (H42D & H120D), and QPs1 (H42D & H98D) were constructed by 
annealing each of the two mutated oligonucleotides with an ampicillin repair 
oligonucleotide to the single-stranded pSelect/QPs1. The triple mutant, QPs1 (H42D, 
H105D, H120D) was constructed by annealing each of the three mutated oligonucleotides 
with an ampicillin repair oligonucleotide to the single-stranded pSelect/QPs1. The hexad 
mutant (except H26) and septenary mutant were constructed by annealing H26D, H70D, 
H85D, H98D-mutated oligonucleotides with an ampicillin repair oligonucleotide to the 
single-stranded pSELECT/QPs1 (H42, 105, 120D). 
 A 432 bp BamHI–HindIII fragment containing mutated QPs1 was excised from 
pSelect/QPs1m and cloned into BamHI and HindIII of pGEX2TH vector to generate 
pGEX2TH/QPs1m, which was then transformed into JM109 cells. Mutations were 
confirmed by DNA sequencing of both pSelect/QPs1m and pGEX2TH/QPs1m. 
pGEX2TH/QPs1m plasmids were further transformed into host E. coli DH5α cells. 
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Transformants expressing the GST-QPs1m protein were identified by immunological 
screening of colonies with antibodies against the QPs1.  
Production and Purification of Recombinant Wild-type and Mutant QPs1.   
 250 ml of an overnight grown culture of E. coli DH5α/pGEX/QPs1 was used to 
inoculate 12 liters of enriched medium (2% Selected peptone 140, 0.2% Na2HPO4, 0.1% 
KH2PO4, 0.8% NaCl, 1.5% Select yeast extract, and 0.2% glucose) containing 2.5 mM 
betaine, 440 mM sorbitol, and 100 µg/ml ampicillin, and incubated at 37°C with vigorous 
shaking until the OD660 nm reached 0.7. The culture was cooled to 27°C and IPTG was 
added to a final concentration of 0.5 mM to induce the synthesis of the GST–QPs1 fusion 
protein. Cells were grown at 27°C for 3 hours before they were harvested by 
centrifugation at 8000xg for 15 min. The cell paste (43 g) was suspended in 80 ml of PBS 
buffer (20 mM sodium/potassium phosphate, pH 7.3, containing 150 mM NaCl) and 
sonicated at 30 milliwatts at 0 °C with four 20-s pulses at 3 to 4 min intervals. During 
sonication, protease inhibitor, PMSF (phenylmethylsulfonyl fluoride), 100 mM in 
absolute alcohol, was added to a final concentration of 1 mM. Triton X-100 was added to 
the broken cell suspension to a final concentration of 1% (w/v). This mixture was stirred 
gently on ice for 1 h before being centrifuged at 30,000 x g for 20 min. The supernatant 
obtained was mixed with an equal volume of glutathione–agarose gel equilibrated with 
PBS. The mixture was gently shaken for 2 h at 4 °C and packed into a 2.5x13 cm column. 
The column was washed with 800 ml of 50 mM Tris–Cl buffer, pH 7.5, then with 100 ml 
of 50 mM Tris–Cl, pH 8.0, containing 0.1 mM glutathione and 0.25 M sucrose, and 
finally eluted with 50 mM Tris–HCl, pH 8.0, containing 5 mM glutathione and 0.25 M 
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sucrose.  Fractions containing the GST-QPs1 fusion protein were pooled and dialyzed 
against 50 mM Tris–Cl, pH 8.0, containing 0.25 M sucrose, overnight, with two changes 
of buffer. The dialyzed sample was concentrated with a Centricon-10 to a protein 
concentration of 10 mg/ml, mixed with glycerol to a final concentration of 10%, and 
frozen at -80°C until use.  QPs1 protein was released from GST-QPs1 fusion protein by 
thrombin digestion (1 µg/500 µg of protein) and recovered by gel filtration using a FPLC 
superose-12 column.  Recombinant QPs1 mutants were obtained in the same manner as 
the wild type protein. 
Enzyme Preparations and Assays 
 Succinate-Q reductase (4), succinate dehydrogenase (5), and QPs (6) were 
prepared and assayed as previously reported. Succinate–ubiquinone reductase was 
assayed for its ability to catalyze the Q-mediated DCPIP reduction by succinate. One ml 
assay mixture contains 100 mmoles of sodium/potassium phosphate buffer, pH 7.4, 
50 nmoles of DCPIP, 20 mmoles of succinate, 10 nmoles of EDTA, 16 nmoles of Q2 and 
0.1 mg of Triton X-100. The reduction of DCPIP was followed by an absorption decrease 
at 600 nm using a millimolar extinction coefficient of 21 cm−1 mM-1. 
Absorption spectra and spectrophotometric activity assays were performed at room 
temperature in a Shimadzu UV-2101PC spectrometer. Protein concentration was 
determined by the Lowry method (7) using bovine serum albumin as standard. The heme 
content was determined from the reduced pyridine hemochromogen spectra using a 
millimolar extinction coefficient of 34.6 cm−1 mM-1 for the absorbance difference 
between 557 nm and 600 nm (8). Analytical SDS-PAGE was performed in a Bio-Rad 
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Mini-Protein dual slab cell using the gel system of Schägger et al. (9), with modifications 
(10). Western blots were performed as previously described (11). The EPR measurements 
were made with a Bruker ER-200D equipped with an Air Product Heli-Tran System.  
EPR settings are detailed in figure legends. 
 
RESULTS AND DISCUSSION 
Purity and Properties of Purified Recombinant QPs1 
 When purified recombinant GST-QPs1 fusion protein preparation was subjected 
to SDS-PAGE (lane 3 of Figure 7 (A)), three major protein bands were observed: one 
with an apparent molecular weight of 41 kDa which accounted for 65% of the total 
protein, one with a molecular weight of about 68 kDa that accounted for 5% of the total 
protein and one smear band with the molecular weight span from 26.5 to 27 kDa that 
accounted for 30% of the total protein. The 41 kDa protein was GST–QPs1 fusion 
protein, the 26.5–27 kDa smear band contained incomplete GST–QPs1 fusion proteins, 
and the 68 kDa band was a contaminant protein. These assignments were based on the 
observation that both 41 kDa and 26.5–27 kDa proteins reacted with antibodies against 
QPs1 (lane 3 of Figure 7 (B)) and produced GST (Mr=26000 Da) upon thrombin 
digestion (see lane 4 of Figure 7 (A)). To date, we have been unable to obtain a GST–
QPs1 preparation free of incomplete GST–QPs1 proteins, with a reasonable yield. 








Figure 7. Identity of recombinant QPs1. (A) SDS-PAGE of isolated recombinant QPs1. 
Lane 1, molecular weight standard; lane 2, bovine heart mitochondrial succinate–
ubiquinone reductase; lane 3, glutathione–agarose gel purified recombinant GST–QPs1; 
lane 4, thrombin digested recombinant GST–QPs1; and lane 5, purified recombinant 
QPs1. The high resolution SDS-PAGE gel of Schägger et al. (9) was used. (B) The 
proteins on the gel of (A) were electrophoretically transferred to a nitrocellulose 
membrane, without staining, and reacted with anti-QPs1 antibodies. Protein A 
horseradish peroxidase conjugate was used as the second antibody. 
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glutathione–agarose gel prior to elution of GST–QPs1 with 5 mM glutathione decreased 
the amount of incomplete GST–QPs1 proteins in the final preparation. 
 QPs1 was progressively released from GST–QPs1 fusion protein by treatment 
with thrombin (0.5 unit/mg protein) at room temperature. The reaction was completed 
after 30 min of incubation at room temperature. Recombinant QPs1 released from GST 
becomes highly aggregated and was recovered as a precipitate. The aggregation of QPs1 
in aqueous solution was apparently due to the presence of hydrophobic domains, the three 
transmembrane helices, in the protein (10). Inclusion of 0.01% of dodecyl maltoside 
during thrombin digestion did not affect thrombin activity and permited recovery of QPs1 
in a soluble (detergent dispersed) form. When this thrombin digested fusion protein was 
applied to a Superose-12 FPLC column equilibrated with 50 mM Tris–Cl, pH 7.8, 
containing 0.01% dodecyl maltoside, purified recombinant QPs1 was recovered in the 
void volume, indicating that purified QPs1, in 0.01% dodecyl maltoside, was still highly 
aggregated, with apparent molecular mass of over 1 million. The Superose-12 column 
chromatography separated uncleaved GST–QPs1 fusion protein, released GST, and 
thrombin, from QPs1. When the QPs1 containing fraction recovered from the Superose-
12 column was subjected to SDS-PAGE, a single band, corresponding to the third subunit 
(QPs1) of purified succinate–ubiquinone reductase, was observed (lane 5 of Figure 7 
(A)). However, when this purified recombinant QPs1 was subjected to partial N-terminal 
amino acid sequencing, two extra residues, glycine and threonine, were observed. The 




Reconstitution of Cytochrome b560 from Recombinant QPs1 and Hemin Chloride   
 Although QPs1 was believed to be cytochrome b560 with bis-histidine ligands 
(12), isolated recombinant QPs1, obtained from cultures with or without aminolevulinic 
acid, contained little cytochrome b560 heme. Probably the lack of cytochrome b560 heme 
in recombinant QPs1 resulted from the inability of E. coli DH5α/pGEX-QPs1 cells to 
either incorporate heme into apoprotein or to produce enough heme. In other words, the 
expressed GST–QPs1 fusion protein had the correct structure for heme ligation and 
cytochrome b560 could be formed if heme was available. One way to test these 
possibilities is to reconstitute recombinant QPs1 in vitro with heme chloride to form 
cytochrome b560. Reconstitution was first attempted with the fusion protein because it is 
soluble in aqueous solution.   
 When hemin chloride in DMSO was added to GST-QPs1, the maximum 
absorption peak (Soret band) of the oxidized form of heme progressively shifted from 
398 nm to 411 nm, with increasing absorption intensity, during the incubation (see Panel 
A of Figure 8).   It took 2 h to complete the spectral red shift and to reach maximum 
absorption. When heme-reconstituted sample  was reduced with dithionite, it had 
symmetrical α-absorption at 559.5 nm, a broad β-absorption peak at 530 nm, and Soret 
absorption at 425 nm. These absorption characteristics were identical to those of 
cytochrome b560 in an isolated, reconstitutively active QPs preparation (6). Thus, 
cytochrome b560 was restored to GST–QPs1 fusion protein by heme addition. 
 Since GST from Scistosoma japonicum in recombinant GST–QPs1 contains 6 










Figure 8. Restoration of cytochrome b560 to isolated recombinant GST–QPs1 fusion 
protein by heme. Three µl aliquots of hemin chloride (6.18 mM) in DMSO were added to 
3 mg of purified recombinant GST–QPs1 fusion protein (panel A) and 3 mg of GST 
(panel B) in 1 ml, 50 mM Tris–Cl buffer, pH 8.0, containing 0.25 M sucrose. The 
mixtures were incubated at room temperature and absorption spectra were recorded from 
time to time during the incubation period. Total incubation time was about 2 hrs. When 
the oxidized Soret absorption peak no longer changed (——), a small amount of 
dithionite was added and spectra recorded (- - -). The inserts are the difference spectra of 
the dithionite-reduced vs. oxidized form at the α and β absorption regions.  
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that the bis-histidine ligands of reconstituted cytochrome b560 in GST–QPs1 were 
provided by the QPs1, and not by the GST moiety. This was achieved by comparing the 
absorption spectra and EPR characteristics of heme-ligated GST with those of heme-
ligated GST–QPs1. Recombinant GST was produced in DH5α/pGEX cells and purified 
by glutathione–agarose gel. Since, after addition of heme to purified recombinant GST, 
under conditions identical with those for GST–QPs1, no cytochrome b560 spectrum was 
produced (panel B, Figure 8), the bis-histidine ligands of reconstituted cytochrome b560 
were provided by the QPs1 moiety of the fusion protein. The heme-ligated GST had a 
very broad α-absorption at 540 nm in the dithionite-reduced form.  
 Reconstitution of cytochrome b560 into GST–QPs1 was heme concentration 
dependent. When GST–QPs1 was incubated with various amounts of hemin chloride, the 
peak height at 559.5 nm increased as the amount of heme added was increased (Figure 9). 
Maximum reconstitution was reached when the molar ratio of heme to fusion protein 
used in the system was 0.6. When the heme to protein ratio was higher than 0.6, the 
sample had an increased absorbance at 559.5 nm compared to that reconstituted with a 
0.6 molar ratio of heme, but with a discernible broad shoulder at around 580 nm. This 
increased 559.5 nm absorbance was diminished when the sample was treated with 
thrombin (see Figure 9), indicating that excess heme cross ligated to a histidine residue in 
the GST moiety to form a cytochrome b560-like spectra. No change in 559.5 nm 
absorbance was observed with reconstituted cytochrome b560, formed with less than 0.6 
molar ratio of heme, after thrombin digestion. A millimolar coefficient for reconstituted 






Figure 9. Effect of heme concentration on the reconstitution of cytochrome b560 in 
recombinant GST–QPs1 fusion protein. One ml aliquots of purified recombinant GST–
QPs1 fusion protein, 0.7 mg/ml, in 50 mM Tris–Cl, pH 8.0, were added to 3 µl of DMSO 
containing indicated concentrations of hemin chloride. Mixtures were incubated at room 
temperature for 2 h and difference spectra between the oxidized and reduced forms of 
each sample were measured before (×) and after thrombin digestion ( ). The thrombin 
digestion was carried out with 0.01 unit/µg protein at room temperature for 1 h.
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spectra between the dithionite-reduced and the oxidized forms. This value is about half 
that determined for cytochrome b560 in isolated QPs.  
 The less than unit reconstitution can be explained by one or more of the 
following: (1) the presence of some incomplete GST–QPs1 proteins in the isolated fusion 
protein preparation; (2) partial availability of one of the histidine ligands in the QPs1 
moiety resulting from the aggregation of isolated fusion protein in aqueous solution. 
When this partially available histidine residue is completely ligated by heme, excess 
heme is ligated to a histidine residue in the GST moiety to form a cytochrome b560-like 
spectra which is diminished by thrombin digestion; (3) the two histidine ligands are from 
different QPs1 molecules. In this case, only one histidine residue of each QPs1 is 
involved. Results described in the next section seem to support the first possibility. 
EPR Characteristics of Heme-Reconstituted Wild-type QPs1: 
 Figure 10 shows EPR characteristics of heme-ligated GST–QPs1, heme-ligated 
GST, and free heme. Reconstituted cytochrome b560 in GST–QPs1 showed an EPR peak 
at g=2.91 (trace A of Figure 10), which differed completely from the EPR characteristics 
of heme-treated GST (g=3.50 and g=3.86, trace C of Figure 10) and of free heme (a 
broad peak with g=3.80, trace D of Figure 10). When reconstituted cytochrome b560 in 
GST–QPs1 was treated with thrombin, no change in EPR characteristics was observed 
(see trace B of Figure 10). These supported the results obtained from absorption spectra 
which indicated that the bis-histidine ligands of cytochrome b560 were provided by the 
QPs1 moiety. The g=2.91 EPR signal observed for reconstituted cytochrome b560 in 
recombinant QPs1 corresponded to one of the two EPR signals (g=2.91 and g=3.07) 
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Figure 10. EPR spectra of reconstituted cytochrome b560, thrombin-treated reconstituted 
cytochrome b560, heme-added GST, and free heme. 18 µl aliquots of hemin chloride, 
8.0 mM, in DMSO were added to 0.9 ml of 50 mM Tris–Cl buffer, pH 8.0, containing 
(A) GST–QPs1 fusion protein, 10 mg/ml; (C) purified recombinant GST, 10 mg/ml; (D) 
none. The mixtures were incubated at room temperature, with stirring, for 2 h prior to 
EPR measurement. Trace (B) was taken after treatment of (A) with thrombin 
(0.01 unit/µg protein) for 1 h at room temperature. The EPR instrument settings were: 
modulation frequency, 100 kHz; modulation amplitude, 20 G; time constant, 0.5 s; 
microwave frequency, 9.42 GHz; microwave power, 20 mW; scan rate, 200 G/s; and 
temperature, 11 K. 
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observed for cytochrome b560 in isolated QPs. This g=2.91 signal of cytochrome b560 in 
isolated QPs was not affected by the addition of succinate dehydrogenase to QPs to form 
succinate–ubiquinone reductase (6).  
 The incomplete GST–QPs1 (C-terminal truncated QPs1) proteins accounted for 
about 30% of the total protein in the isolated fusion protein preparation (see line 3 of 
Figure 7 (A)). These C-terminal truncated QPs1 proteins were probably missing one or 
both of the two histidine residues in QPs1 since the apparent molecular masses of these 
proteins were 500–1000 Da. If the bis-histidine ligands of reconstituted cytochrome b560 
in GST–QPs1 were provided by the intact QPs1 moiety, 1 mol of heme ligated into 1 mol 
of intact QPs1–GST in the preparation would give maximum reconstitution with a 0.6 
molar ratio of heme added. This idea was supported by the recovery of thrombin treated 
reconstituted cytochrome b560 in QPs1, which had a heme to protein ratio of 0.9, by a 
Sepharose-12 column chromatography, GST–QPs1 had only a heme to protein ratio of 
0.57. Furthermore, the amount of cytochrome b560 restoration into GST–QPs1 correlates 
with the amount of intact QPs1 presented in the fusion protein preparation. Addition of 
heme to a GST–QPs1 preparation enriched with incomplete QPs1–GST proteins (to 
about 80%), gave maximum reconstitution (2 nmol/mg) when the heme to protein ratio in 
the system was 0.18. The incomplete GST–QPs1 enriched preparation was obtained in a 
0.1 mM glutathione washing of GST–QPs1 adsorbed on glutathione–agarose gel during 
purification.  
 To date we have been unable to reconstitute cytochrome b560 reconstituted 
recombinant QPs1 with succinate dehydrogenase to form succinate-Q reductase. We 
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observed no change in the absorption spectra, EPR characteristics, and carbon monoxide 
reactivity of reconstituted cytochrome b560 in GST–QPs1 or in QPs1 upon addition of 
succinate dehydrogenase. This indicates that no specific interaction occurs between 
succinate dehydrogenase and recombinant QPs1. The failure of reconstituted cytochrome 
b560 in GST–QPs1 or in QPs1 to interact with succinate dehydrogenase to form 
succinate–ubiquinone reductase may be due to a requirement of QPs2 or QPs3 for this 
interaction.  
Identification of Amino Acid Residues of QPs1 Involved in Ligation of Heme b560  
 QPs1 contains seven histidine residues at positions 26, 42, 70, 85, 98, 105, and 
120. To locate the heme-ligating residues, we altered each of these residues to aspartic 
acid and asparagine, by site-directed mutagenesis followed by spectral (absorption and 
EPR) characterization of heme-reconstituted recombinant QPs1 mutants. Figure 11 shows 
absorption spectra of heme-reconstituted recombinant QPs1 mutants. The absorption 
spectra of heme-reconstituted wild type QPs1 was included for comparison. The addition 
of hemin chloride to the H26D, H26N, H42D, H42N, H70D, H70N, H85D, H85N, 
H105D, or H105N mutant yielded absorption spectra similar to those of reconstituted 
wild type, indicating that H26, H42, H70, H85, and H105 were not involved in heme 
ligation. However, the Soret absorption peaks of heme-reconstituted mutants H98D, 
H98N, H120D and H120N were very different, with a 14 nm red shift of the peak 
maximum (from 424 nm to 438 nm) and a drastic decrease in absorbance (panel F, H, I, 
and J of Figure 11), indicating that His-98 and His-120 of QPs1 were involved in heme 




Figure 11. The dithionite-reduced minus –oxidized spectra of thrombin treated, heme-
reconstituted mutant QPs1 fusion proteins. The panels are as follows: A, wild type; B, 
H26D; C, H42D; D, H70D; E, H85D; F, H98D; G, H105D; H, H120D; I, H98N; J, 
H120N; K, H26D, H70D; L, H42D, H98D; M, H42D, H105D, H120D; N, H98D, 
H120D; O, H42D, H70D, H85D, H98D, H105D, H120D; and P, H26D, H42D, H70D, 
H85D, H98D, H105D, H120D.
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H120D (panel N), triple mutant, H42D, H105D, H120D (panel M), hexa mutant, H42D, 
H70D, H85D, H98D, H105D, H120D (panel O), and hepta mutant, H26D, H42D, H70D, 
H85D, H98D, H105D, H120D (panel P) were reconstituted with hemin chloride, no 
cytochrome b560 spectral characteristics were observed. 
 The crystal structure from E. coli SQR revealed the possible heme ligands for the 
cytochrome b560 (14). They were H84 from SdhC subunit and H71 from SdhD subunit. 
Unlike the FP and IP subunits, which have high sequence similarities through different 
species, the anchor polypeptides from different species show little apparent sequence 
similarity. In fact, the number of subunits and heme content are different between 
species, varying from one subunit containing two hemes like Bacillus subtilis, two 
subunits containing two hemes like Thermoplasma acidophilum, and two subunits 
containing no heme like Saccharomyces cerevisiae (15). So, the fact that we were able to 
demonstrate that the bis-histidine ligands were from QPs1 shows the variety of this 
anchoring protein among different spices. Another possibility could be unspecific ligand 
binding from other histidine residues in QPs1 under the current experimental conditions.   
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PURIFICATION AND CRYSTALLIZATION OF NADH 






A purification procedure for NADH dehydrogenase was developed. This 
procedure involves acid extraction in the presence of organic solvent followed by 
ammonium sulfate fractionation, and DEAE Sepharose column chromatography. The 
purified NADH dehydrogenase contains 3 protein subunits with apparent molecular 
weight of 51, 24, and 10 kD. It catalyzed oxidation of NADH by artificial electron 
acceptor ferricyanide with specific activity of 471 µmol Fe(CN)63- reduced/(min mg) 
protein. The purified NADH dehydrogenase contained one FMN, five irons, and two 
EPR detectable iron sulfur clusters, one [4Fe-4S] and one [2Fe-2S]. Preliminary attempts 






Complex I serves as the entry point for electrons from NADH into the respiratory 
chain of mitochondria. Due to the extreme structural complexity, the difficulty of 
applying optical spectroscopy to analyze the redox state of intrinsic chromophores within 
the membrane, and the absence of inhibitors that block the pathway at specific 
intermediate sites, there is still uncertainty about the electron pathway of complex I.  
The FP fragment of bovine complex I, also called NADH dehydrogenase, has 
been extensively studied, and is considered as the entry point of electron translocation of 
this complex.  Its FMN and NADH binding ability, the presence of iron-sulfur clusters N-
1b and N-3, and simplicity to prepare in comparison with the whole enzyme complex, 
make it an attractive candidate to be the first fully understood subcomplex of this 
complicated complex. 
Since 1952, various forms of the mitochondrial NADH dehydrogenase have been 
isolated and studied (1,2). The schemes of these preparations are varied from one to 
another, but in general, they involve the following steps. First, solublizing agents such as 
ethanol, thiourea, snake venom, and NaClO4 are used to extract the soluble part of 
proteins out of either various preparations of submitochondrial particles or complex I. 
Second, combining either several or all of the treatments such as changing the pH, alteing 
the temperature, fractionation by ammonium sulfate, dialysis, and column 




We adopted and modified the NADH dehydrogenase purification method 
developed by Mackler (3), which uses ethanol as solublizing agent, and then further 
purify the enzyme through a series of steps. The specific activity from NADH to artificial 
electron acceptor ferricyanide was used to monitor the enzymic activity of this 
purification. The high resolution sodium dodecyl sulfate (SDS) polyacrylamide gel 













Preparation of Submitochondrial Particles (SMP) from Bovine Heart 
About 10 pounds of trimmed beef hearts, which were free of fat and connective 
tissues, were taken from a -20°C freezer, 12 hours prior to preparation and left at the 
room temperature for one hour, then moved to 4°C. Heart muscle was ground in a power-
driven meat grinder and ground meat was divided into about 600 g per portion. Each 
portion of meat was placed into a blender, adding 1.8 L of 10 mM K2HPO4 and about 5.5 
ml of 6 N NaOH, and blended for 30 seconds from low to high speed. 6 N NaOH was 
used to adjust the pH of the mixture to around 7.0~7.4 before blending for another 30 
seconds. The blended mixture was centrifuged for 15 minutes at 2,800 rpm in a J-6 rotor 
(Beckman). The turbid supernatant was collected and poured through eight layers of 
cheese cloth. The precipitate was suspended with about 500 ml of 20 mM Na/K 
phosphate at pH 7.4, and centrifuged for 15 minutes at 2,800 rpm in a J-6 rotor. Again, 
the supernatant was collected and poured through eight layers of cheese cloth. For each 6 
liters of combined filtrate, pH was adjusted to 5.5 with 2 N acetic acid, and then 
centrifuged for 25 minutes at 4,000 rpm in a J-6 rotor. The precipitate was homogenized 
in ~ 900 ml of 0.1 M phosphate borate buffer at pH 7.8. The mixture was centrifuged for 
1 hour in a Ti45 rotor at 45,000 rpm. The precipitate was homogenized in water to a final 






Purification of NADH Dehydrogenase from SMP  
 In order to adjust the protein concentration and to further reduce the salt 
concentration, 600 ml of SMP were mixed with cold water to a final volume of 1.6 L. 
The pH was adjusted from around pH 7.0 to 5.5 with 2 N acetic acid. The mixture was 
centrifuged for 20 minutes at 4,000 rpm in a J-6 rotor. The precipitate was briefly 
suspended in cold water in the same centrifuge bottle to a final volume of about 800 ml, 
and centrifuged again for 20 minutes at 4,000 rpm. The precipitate was homogenized 
with cold water to give a final protein concentration of 40 mg/ml in about 400 ml. The 
sample was adjusted to pH 4.8 with 2 N acetic acid and 100% ethanol was added to give 
a final concentration of 9%. The mixture was placed into a water bath with a temperature 
of 55°C with constant stirring until the sample temperature reached 40°C. The sample 
was left at 40°C for 10 minutes with constant stirring. After that, the sample was 
immediately placed in an ice-salt water bath, with constant stirring, until it reached 4°C. 
The sample was centrifuged for 20 minutes at 45,000 rpm in a Ti45 rotor. A gold-light 
red colored supernatant, named S1, was collected.  
Fine ammonium sulfate was slowly added to S1 with constant stirring to give a 
final 57% Am2SO4 saturation. After stirring for 10 minutes at 4°C, the mixture was 
centrifuged for 20 minutes at 45,000 rpm. The light yellow-brown color precipitate was 
collected and dissolved in about 3 ml of 5 mM K2HPO4/KH2PO4 (K/K phosphate) buffer, 
pH 6.5. The sample was then centrifuged for 10 minutes at 19,000 in a JA-20 rotor, in 




Solution, named P2, was collected and applied to a G-25 column, which was 
equilibrated with 5 mM K/K phosphate at pH 6.5, with a sample volume to column 
volume ratio of about 5%. This reduces the sample salt concentration as is required for 
DEAE-Sepharose column chromatography. The G-25 effluent, with brownish color, 
named F3, was collected, and immediately applied to a DEAE-Sepharose CL-6B column 
equilibrated with 5 mM K/K phosphate at pH 6.5. The column was washed with 
equilibration buffer until no color was observed in the effluent. The NADH 
dehydrogenase was eluted with 5 mM K/K phosphate at pH 6.5 containing 25 mM NaCl. 
The sample was in red/brown color, named F4.  
The protein concentration of F4 was determined by absorbance measurements at 
278 nm with a specific absorptivity of 2.44 ml/(mg cm), which was determined by 
Bradford method, using Bovine Serum Albumin (BSA) as standard. F4 was then adjusted 
to protein concentration of ~1 mg/ml by the same eluting buffer. Fine ammonium sulfate 
was slowly added, with constant stirring, to give a final 60% saturation. The turbid 
solution was stirred at 0°C for10 minutes and centrifuged for 15 minutes at 19,000 rpm in 
a JA-20 rotor. The precipitate was collected and dissolved in 100 µl of 5 mM K/K 
phosphate at pH 6.5. This fraction was named P5. Normally a protein concentration of 
~55 mg/ml, determined by the Bio-Rad protein assay, was obtained. If P5 was to be used 
for crystallization attempts or for storage (-80°C freezer), the following substances were 
added: dithiothreitol (DTT) (final concentration of 5 mM), cytochrome c oxidase (CcO) 
(0.002 mg/mg protein), cytochrome c (0.0005 mg/mg protein), and sodium ascorbate 
(NaAsc) (final concentration of 10 mM). Otherwise, P5 was used in the next purification 




A 200 µl aliquot of P5 at protein concentration of ~20 mg/ml in 5 mM K/K 
phosphate, pH 6.5 was applied to a SuperdexTM 200 column (Pharmacia), equilibrated 
with 10 mM Na2HPO4/NaH2PO4 (pH 7.4) buffer containing 10 mM NaAc (pH 7.4), 10 
mM DTT, 10 mM NaAsc, and 1 mM NaN3. The flow rate was 0.5 ml/min, and the 
sample collecting size was 0.5 ml/tube. The collected sample, colored light brown, named 
F6, was concentrated by CentriconTM 30 to ~20 mg/ml. Whether for crystallization 
attempts or for storage (-80°C freezer), the following substances were added: DTT (final 
concentration of 5 mM), CcO (0.002 mg/mg protein), cytochrome c (0.0005 mg/mg 





RESULTS AND DISCUSSION 
Purification of NADH Dehydrogenase 
 Table III summarizes the purification data. Prior to acid extraction in ethanol, the 
salt concentration in preparation has to be lowed. Therefore, repeat dilution with water 
was needed to reduce the salt concentration. SMP was suspended in phosphate borate 
buffer with pH around 7.5. After diluted to three times with water, pH was adjusted to 5.5 
instead of 4.8. This step was found necessary because it removes excess amount of blood 
remaining in the SMP, also it helps to further decrease the buffer capacity, which 
becomes critical later on when only small amount of acid would be needed to adjust the 
pH to 4.8 with protein concentration as high as 35 mg/mL.  
 It should be noted that when collecting the supernatant (S1) from acid/ethanol 
extraction, small amount of floating precipitates were found. These floating precipitates 
should be removed before proceeding to ammonium sulfate fractionation step. It’s 
necessary to centrifuge S1 one more time in order to remove the precipitate. 
 The ammonium sulfate fractionation step, which was designed to concentrate and 
further purify the S1 fraction, caused 50% loss of total activity and 59% of total proteins, 
and therefore, should be modified. One possible reason for this loss could be the low pH 
from the previous step of acid extraction (pH 4.8). Without adjusting the pH back to 





Summary of purification procedures, protein concentration and recovery, and specific 
activity at each step.  
Sample Volume [Protein] Total 
Protein










mg/ml 140 mg 100 66 23100 100 165 1
After G-25 
(F3)
5.5ml 7 mg/ml 38.5 mg 28 1900 10450 45 271 1.6
Superdex 
200 (F6) 375µl 20 mg/ml 7.5mg 5.4 9425 3535 15 471 2.9






43.8 mg 31 3300 11550 50 264











*Activity is based on NADH to Fe(CN)63-, monitor @ 420 nm, the reduction of Fe(CN)63-.
** Specific activity un
 









iron sulfur clusters to denature. Also considering other precipitant other than ammonium 
sulfate might prevent the loss of activity as well.  
 As shown in Table III, the F4 fraction, which was the eluted from the DEAE-
Sepharose CL-6B column with 5 mM K/K phosphate at pH 6.5 containing 25 mM NaCl, 
recovered 60% of the total activity, but only 32% of the total protein, and 1.8 fold 
increase of specific activity. This was consistent with the observation that large portion of 
the protein, which couldn’t be eluted out with 25 mM NaCl, bound tightly with the 
column. When eluting buffer containing 1 M NaCl was used, most of the protein was 
released from the column but with no detectable activity. This indicates that protein 
denaturation occurred. Currently, no solution to this problem has been found. 
 After Am2SO4 fractionation, P5, with 4 subunits as shown in panel A of Figure 
12, was subjected to column chromatography by passing through a SuperdexTM 200 
column. The effluent, named F6 (as shown in panel B of Figure 12), had only 3 subunits, 
didn’t show any improvement of specific activity. Although the answer to this question 
wasn’t clear, it’s possible that denaturation of NADH dehydrogenase had occurred during 
the column chromatography, which results in the loss of activity, or the fourth subunit in 
P5 is actually critical for the activity.  
Subunit Composition of P5 and F6 in NADH Dehydrogenase  
Figure 12 shows SDS-PAGE of P5 and F6. P5 contains 4 subunits, with apparent 
molecular weight of 51, 24, 10, and 9 kD, and F6 contains 3 subunits, with apparent 









Figure 12. Protein composition and identification of NADH dehydrogenase. SDS-PAGE 
of fractions P5 (A) and F6 (B), right lane of each figure. The left lanes are molecular 
weight standards. Each band of P5 and F6 was sequenced, and the first 10 amino acids 
are indicated, along with its identity. The high resolution SDS-PAGE gel of Schägger et 




amino acids. By comparing known protein sequences of SwissProt utilizing BLITZ, the 
identification and composition of the three and four subunits (fraction P5 and F6) were 
determined. In both P5 and F6, the compositions are 51, 24, and 10 kDa subunits of FP 
fragment in complex I. The fourth band of P5, however, is identified as Coupling Factor 
6 of bovine complex V (ATP synthase). 
Chemical Composition of NADH Dehydrogenase Preparation 
a. FMN content of P5. 
 Acid-extractable flavin was determined fluorometrically using a Perkin-Elmer 
650-40 Fluorescence Spectrophotometer and FMN (synthetic, from Sigma) as a standard. 
The concentration of the standard was calculated from the difference in absorption at 450 
nm and 530 nm before and after addition of excess dithionite using an extinction 
coefficient of 10.3 mM−1 cm−1 (4). The molar ratio between FMN and P5 was found to be 
1:1, which is consistent with the general consensus that there is one mole FMN per mole 
of complex I and that the FMN probably binds to the 51 kD subunit (5). 
b. Non-heme iron content of P5 and F6.  
By using the method developed by Doeg and Ziegler (6), iron was extracted from 
the sample by thioglycolic and acetic acids. Iron then was released into solution as the 
complex with 4,7-diphenyl-1,10-phenanthroline into isoamyl alcohol. The results show 
that the molar ratio between iron and P5, and iron and F6 were 5.13:1 and 4.98:1, 
respectively. The iron content was lower than expected since there are one [4Fe-4S] and 







Figure 13. High resolution SDS-PAGE of protein samples from each 
purification steps. From left to right, fraction P5, (M) molecular-mass 
markers, fraction F4, F3, P2, and S1. Molecular weights of the marker are 





iron and the FP, instead of about 5:1 in our preparation. The low iron content implies the 
loss in iron sulfur clusters, which results in drop of activities.  
 The specific activities based on NADH to ferricyanide of P5 and F6, as shown in 
Table I, are 480 and 471 µmol Fe(CN)63- reduced/(min mg protein). The specific activity 
is about the same as to the Mackler enzyme, which purified by similar procedure (7). 
Absorption Spectra 
 As shown in Figure 14, the final absorption spectra of P5 and F6 shared similar 
features, with shoulders at about 350 nm (iron sulfur cluster) and 450 nm (flavin protein). 
EPR Spectra of P5 and F6 
 Figure 15 shows EPR spectra of P5 and F6. In part A, both samples show the 
[4Fe-4S] (N3) clusters reducible by dithionite. In part B, both samples show the [2Fe-2S] 
(N1b) clusters reducible by dithionite, but with much lower content compared with part 
A. These results are consistent with previous reports that one [4Fe-4S] (N3) cluster is 
located in the 51 kD subunit of FP and one [2Fe-2S] (N1b) cluster is located in the 21 kD 
subunit of FP (8). The low content of N1b cluster was in concordance with our previous 
finding of lower than expected non-heme iron content, which suggests that there was loss 
of N1b cluster during preparation. 
Stability of NADH Dehydrogenase 
To test the stability of fraction P5, samples were stored in small microfuge tubes 
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Figure 14. Spectra characters of protein samples from each purification steps. 
Each fraction is colored as indicated on the top of figure. All fractions protein 
concentration were adjusted to about 0.5 mg/ml. The UV-2410PC recording 














































Figure 15. EPR spectra of NADH dehydrogenase. EPR spectra of fractions P5 and F6 
have been taken under the condition: A) 5 mM dithionite, 10 mW, and 10 K; B) 1 mM 
NADH, 5 mM dithionite, 5 mW, and 50 K. In part A, both samples are showing the 
[4Fe-4S] (N3) clusters reducible by dithionite. In part B, both samples are showing the 
[2Fe-2S] (N1b) clusters reducible by dithionite, but with much lower content compared 











time. CcO was added at a ratio of 0.002 mg per mg of protein and DTT was added to a 
final concentration of 5 mM. When CcO was added, cytochrome c (0.0005 mg/mg 
protein), and NaAsc (final concentration of 10 mM) were also added at the same time. An 
anaerobic condition was achieved by preparing and storing sample under argon 
atmosphere. As shown in Figure 16, even with addition of DTT (■), P5 lost 90% of its 
activity within 24 hours when exposed to air. Within anaerobic condition, and added with 
DTT (■), P5 lasted 48 hours before it lost 90% of its activity. With the addition of both 
CcO and DTT (■), P5 lasted for 72 hours even though the sample was exposed to air. 
Finally, with the same condition but under anaerobic condition (■), P5 still had 25% of 
its activity after 145 hours. In conclusion, NADH dehydrogenase was easily to be 
oxidized when exposed to air, which results in the loss of its activity. In order to maintain 
enzyme activity, additions of DTT, along with CcO (addition of cytochrome c and 
NaAsc), and under anaerobic condition are essentials. 
Screening for Crystal Growth Conditions  
 The crystal growth of NADH dehydrogenase was first carried out by testing the 
conditions in which similar type of proteins, such as iron-sulfur proteins and 
dehydrogenase, has been successfully crystallized. The following summarizes the various 
conditions for crystallization we have used: 
 Salt: NaCl, (NH4)2SO4,, MgCl2, MgSO4, KCl, None; 
 Buffer: Tris-Cl, HEPES, MOPS, K/K pi; 
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Figure 16. Stability test of fraction P5. Samples were treated under different conditions
 
as indictated with different colored columns. The stability is represented by specific 
activity (S.A.).




 Precipitant: (NH4)2SO4, PEG: 400, 3350, 4000, 6000, (NH4)H2PO4, MgSO4, 
NaCl; 
 Temperature: 4ºC, 13ºC, 25ºC; 
 Others: ethanol, EDTA, anaerobic, glycerol.  
The conditions, which helped the growth of crystals, are underlined and in bold 
letters. In short, the most desirable condition for crystallize NADH dehydrogenase so far 
was dissolving it ( to a final protein concentration of 10-12 mg/mL) in a pH 7.5-8.0 K/K 
phosphate buffer with ~100 mM of KCl, and addition of CcO and DTT as described 
earlier. The best precipitant was PEG 3350, with a final concentration between 6.5% to 
7.2%. An anaerobic condition was required and temperature of 4°C was essential. As 
shown in Figure 17, small protein crystals were obtained from P5 under the above 
conditions. Crystallization was performed in capillary tubes. 
 The commercial available crystallization kit, which contains various buffer 
conditions, with varying pH, precipitant, and buffer system was also used to obtain 
suitable conditions for crystal growth. As shown in Figure 18, P5 and F6 stability was 
described as the amount of precipitation in each condition for every 24 hours during a 
seven-day observation by using a five-point scoring system. From 5 to 0, the protein and 
buffer mixture is from clear to total precipitation. The X-axis of this figure represents the 
reagent sequence of MembFac Kit purchased from Hampton Research. The detailed list 
of reagent formulation is attached at the end of this chapter. The Y-axis represents the 
total score of this seven-day observation. The conditions with low score would be 




                                  






































Figure 17. Protein crystals of P5 in capillary tubes. The 





















Figure 18. Screening tests for crystal growth. Crystallization of fractions P5 and F6 
are scored as the amount of precipitation in each condition for every 24 hours during 
a seven-day observation by using a five-point scoring system. From 5 to 0, the 
protein and buffer mixture is from clear to total precipitation. The X-axis of this 
figure represents the reagent sequence of MembFac Kit purchased from Hampton 




with a 3 µL to 3 µL exception of 41 to 48 in F6 tests. The protein concentration before 
mixture was at ~20 mg/mL. A reservoir solution of 300 mL was added in each well 
during the hanging drop preparation of P5. In the case of F6, 200 µL was added instead 
of 300 µL. All crystallizations were performed under argon atmosphere to achieve 
anaerobic condition. 
 In the tests of P5 crystallization, reagent no. 45 (0.1 M potassium sodium tartrate 
tetrahydrate, 0.1 M Tris hydrochloride pH 8.5, and 0.4 M magnesium sulfate hydrate) 
showed small salt crystals the moment protein was mixed with the reagent. From reagent 
number 45 to 48, phase separation was observed the moment protein was mixed with the 
reagents. P5 was scored the highest at reagent number 40 (0.1 M lithium sulfate 
monohydrate, 0.1 M Tris hydrochloride pH 8.5, 12% v/v 2-methyl-2,4-pentanediol), but 
F6 precipitated within 24 hours in the same condition. With condition number 42 (0.1 M 
Tris hydrochloride pH 8.5 and 0.1 M sodium acetate trihydrate) and number 43 (0.1 M 
Tris hydrochloride pH 8.5 and 0.1 M sodium chloride), both P5 and F6 were scored high. 
Overall, none of the reagent formulas were found helpful for NADH dehydrogenase 
crystallization.  
 As a side note, the scoring system can be improved to a more detailed and 
précised description by adopting the following system which was developed by Hampton 
Research. 1 Clear Drop; 2 Phase Separation; 3 Regular Granular Precipitate; 4 
Birefringent Precipitate or Microcrystals; 5 Rosettes or Spherulites; 6 Needles (1D 
Growth); 7 Plates (2D Growth); 8 Single Crystals (3D Growth < 0.2mm); 9 Single 




Future Direction  
First, the stability of NADH dehydrogenase prepared as described above needs 
improvement. The biggest obstacle of protein crystallization was the denaturation 
resulting from oxidation of the sample.  Therefore, several methods can be utilized to 
improve the stability. 1) Adding and changing reducing reagents, i.e. DTT, NADH, etc, 
to the sample during and after the purification process. 2) Following more strict anaerobic 
conditions, i.e. starting to utilize anaerobic conditions at an earlier stage of the 
purification. A Nitrogen Dry Box could enable us to carry on the purification in a highly 
anaerobic environment. 3) If the first two steps fail to improve the stability of NADH 
dehydrogenase, an alternative purification protocol for this enzyme would be needed. 
Second, the quality of the crystals needs improvement, because the crystals we 
obtained so far were too small to subject to X-ray diffraction. Attempts should be taken to 
modify the conditions for crystallizing NADH dehydrogenase by changing the 
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Solutions for Crystal Growth
MembFac Reagent Formulation
Tube Number Salt
1.    0.1 M Sodium Chloride
2.    0.1 M Zinc Acetate dihydrate
3.    0.2 M Ammonium Sulfate
4.    0.1 M Sodium Chloride
5.    None
6.    None
7.    None
8.    0.1 M Magnesium Chloride hexahydrate
9.    0.1 M Lithium Sulfate monohydrate
10.  0.1 M Sodium Chloride
11.  0.1 M Magnesium Chloride hexahydrate
12.  0.1 M Sodium Chloride
13.  0.1 M Lithium Sulfate monohydrate
14.  0.1 M tri-Sodium Citrate dihydrate
15.  0.1 M Sodium Chloride
16.  None
17.  0.1 M Sodium Chloride
18.  0.1 M Lithium Sulfate monohydrate
19.  0.1 M Magnesium Chloride hexahydrate
20.  None
21.  0.1 M Lithium Sulfate monohydrate
22.  None
23.  0.1 M Lithium Sulfate monohydrate
24.  None
25.  0.1 M Magnesium Chloride hexahydrate
26.  None
27.  0.1 M Lithium Sulfate monohydrate
28.  0.3 M Lithium Sulfate monohydrate
29.  0.1 M Ammonium Sulfate
30.  0.1 M Sodium Chloride
31.  0.1 M Magnesium Chloride hexahydrate
32.  None
33.  0.1 M Ammonium Sulfate
34.  0.1 M Ammonium Sulfate
35.  0.1 M tri-Sodium Citrate dihydrate
36.  None
37.  0.6 M Magnesium Sulfate hydrate
38.  0.6 M Magnesium Sulfate hydrate
39.  0.1 M Lithium Sulfate monohydrate
40.  0.1 M Lithium Sulfate monohydrate
41.  0.1 M di-Ammonium hydrogen Phosphate
42.  None
43.  None
44.  0.1 M di-Ammonium hydrogen Phosphate
45.  0.1 M Potassium Sodium Tartrate tetrahydrate
46.  None
47.  None
48.  0.1 M tri-Sodium Citrate dihydrate
Tube Number Buffer †
1.    0.1 M Sodium Acetate trihydrate pH 4.6
2.    0.1 M Sodium Acetate trihydrate pH 4.6
3.    0.1 M Sodium Acetate trihydrate pH 4.6
4.    0.1 M Sodium Acetate trihydrate pH 4.6
5.    0.1 M Sodium Acetate trihydrate pH 4.6
6.    0.1 M Sodium Acetate trihydrate pH 4.6
7.    0.1 M Sodium Acetate trihydrate pH 4.6
8.    0.1 M Sodium Acetate trihydrate pH 4.6
9.    0.1 M Sodium Acetate trihydrate pH 4.6
10.  0.1 M Sodium Acetate trihydrate pH 4.6
11.  0.1 M Sodium Acetate trihydrate pH 4.6
12.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
13.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
14.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
15.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
16.  0.1 M tri-Sodium Citrate dihydrate pH 5.6 
17.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
18.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
19.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
20.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
21.  0.1 M tri-Sodium Citrate dihydrate pH 5.6
22.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
23.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
24.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
25.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
26.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
27.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
28.  0.1 M n-(2-Acetamido)iminodiacetic Acid pH 6.5
29.  0.1 M HEPES - Sodium pH 7.5
30.  0.1 M HEPES - Sodium pH 7.5
31.  0.1 M HEPES - Sodium pH 7.5
32.  0.1 M HEPES - Sodium pH 7.5
33.  0.1 M HEPES - Sodium pH 7.5
34.  0.1 M HEPES - Sodium pH 7.5
35.  0.1 M HEPES - Sodium pH 7.5
36.  0.1 M HEPES - Sodium pH 7.5
37.  0.1 M HEPES - Sodium pH 7.5
38.  0.1 M HEPES - Sodium pH 7.5
39.  0.1 M HEPES - Sodium pH 7.5
40.  0.1 M Tris Hydrochloride pH 8.5
41.  0.1 M Tris Hydrochloride pH 8.5
42.  0.1 M Tris Hydrochloride pH 8.5
43.  0.1 M Tris Hydrochloride pH 8.5
44.  0.1 M Tris Hydrochloride pH 8.5
45.  0.1 M Tris Hydrochloride pH 8.5
46.  0.1 M Tris Hydrochloride pH 8.5
47.  0.1 M Tris Hydrochloride pH 8.5
48.  0.1 M Tris Hydrochloride pH 8.5
Tube Number Precipitant
1.    12% v/v 2-Methyl-2,4-pentanediol 
2.    12% w/v Polyethylene Glycol 4000
3.    10% w/v Polyethylene Glycol 4000
4.    12% v/v Isopropanol
5.    12% w/v Polyethylene Glycol 4000 
6.    1.0 M Ammonium Sulfate
7.    1.0 M Magnesium Sulfate heptahydrate
8.    18% v/v Polyethylene Glycol 400
9.    1.0 M mono-Ammonium dihydrogen Phosphate 
10.  12% w/v Polyethylene Glycol 6000
11.  12% w/v Polyethylene Glycol 6000
12.  18% v/v Polyethylene Glycol 400
13.  12% w/v Polyethylene Glycol 4000
14.  10% v/v Isopropanol
15.  12% v/v 2-Methyl-2,4-pentanediol
16.  1.0 M Magnesium Sulfate heptahydrate
17.  12% w/v Polyethylene Glycol 4000
18.  12% w/v Polyethylene Glycol 6000
19.  4% v/v 2-Methyl-2,4-pentanediol
20.  0.1 M Sodium Chloride
21.  4% v/v Polyethylene Glycol 400
22.  1.0 M Ammonium Sulfate
23.  12% w/v Polyethylene Glycol 4000, 2% v/v Isopropanol
24.  1.0 M di-Ammonium hydrogen Phosphate
25.  12% w/v Polyethylene Glycol 6000
26.  12% v/v 2-Methyl-2,4-pentanediol
27.  1.0 M Magnesium sulfate hydrate
28.  4% v/v Polyethylene Glycol 400
29.  0.5 M di-Sodium hydrogen Phosphate dihydrate
0.5 M di-Potassium hydrogen Phosphate
30.  10% w/v Polyethylene Glycol 4000
31.  18% v/v Polyethylene Glycol 400
32.  1.0 M Potassium Sodium Tartrate
33.  18% v/v Polyethylene Glycol 400
34.  10% w/v Polyethylene Glycol 4000
35.  12% v/v 2-Methyl-2,4-pentanediol
36.  1.0 M tri-Sodium Citrate dihydrate
37.  4% v/v Polyethylene Glycol 400
38.  4% v/v 2-Methyl-2,4-pentanediol
39.  0.1 M Potassium Sodium Tartrate
40.  12% v/v 2-methyl-2,4-pentanediol
41.  0.5 M di-Sodium hydrogen Phosphate dihydrate
0.5 M di-Potassium hydrogen Phosphate
42.  0.1 M Sodium Acetate trihydrate
43.  0.1 M Sodium Chloride
44.  12% w/v Polyethylene Glycol 6000
45.  0.4 M Magnesium Sulfate hydrate
46.  0.2 M Lithium Sulfate monohydrate
47.  0.5 M Ammonium Sulfate
48.  5% v/v Polyethylene Glycol 400
† Buffer pH is that of a 1.0 M stock prior to dilution with
other reagent components. pH with HCl or NaOH.




FAST KINETIC STUDY OF BOVINE HEART MITOCHONDRIA 





 Bovine heart mitochondria bc1 complex catalyzes the transfer of electrons from 
ubiquinol to cytochrome c. The bifurcation of quinol oxidation at the Qo site and quinone 
reduction at the Qi site are the key features of the Q-cycle mechanism for electron 
transfer and proton translocation (1,2). The X-ray crystallographic studies show various 
positions of [2Fe-2S] in different crystal forms and in the presence of different Qo site 
inhibitors (3-5), indicating a mobile ISP extramembrane domain. The direct proof of the 
functional significance of such movement is from molecular genetic manipulation of the 
bacterial cytochrome bc1 complex. Decreasing the flexibility of the neck region by 
introducing proline substitutions or other amino acid deletions, greatly reduced electron 
transfer activity and increased the activation energy of the reaction (6). Also, formation 
of a disulfide bond between two engineered cysteines in the neck region near the 
transmembrane helix drastically reduced the electron transfer activity, while release of 
the disulfide bond by reduction or alkylation of the regenerated cysteines restored the 
activity (7).  
 Because of the difficulty of following the reduction of ISP optically and the 
relatively long mixing dead time of conventional stopped-flow apparatuses, direct 
evidence of the early involvement of ISP in ubiquinol oxidation is not available. In this 
chapter, we analyzed the pre-steady state bc1 complex reduction by quinol using stopped-
flow mixing. Utilizing an ultra-fast microfluidic mixer and a freeze-quenching device (8), 
81
coupled with EPR, we have been able to determine the transient state kinetics of ISP 





 Dodecyl-β-D-maltoside (DM), and n-octyl-β-D-glucopyranoside (OG) were 
purchased from Anatrace. 2,3-dimethoxy-5-methyl-6-decyl-1, 4-benzoquinone bromine  
(Q0C10Br)  was synthesized in our laboratory (9). Stigmatellin, myxothiazol, and 
antimycin A were purchased from Sigma. Other chemicals were of the highest purity 
commercially available. 
Enzyme Preparations and Assays 
 Bovine heart mitochondrial cytochrome bc1 complex was prepared as previously 
reported (10). The purified complex was dissolved in 50 mM Tris–Cl buffer, pH 8.0, 
containing 0.33 M sucrose and 0.01% of DM to a cytochrome c concentration of 150 µM 
and 3-maleimido-proxyl (proxyl), a spin label, was added to a final concentration of 75 
µM (from a 50 mM stock solution in ethanol) as an internal standard before the mixture 
was frozen at −80 °C until use. The purified bc1 complex contained 9 nmol of 
cytochrome b and 5.5 nmol of cytochrome c1 per milligram of protein. The 
concentrations of cytochromes b and c1 were determined spectrophotometrically using 
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millimolar extinction coefficients of ∆E562–575 nm=28.5 cm−1 mM−1 and ∆E552–540 nm=17.5 
cm−1 mM−1 for cytochromes b and c1, respectively.  
For activity assay, the cytochrome bc1 complex was diluted with 50 mM 
phosphate buffer, pH 7.4, containing 1 mM EDTA and 0.01% DM to a protein 
concentration of 0.1 mg/ml. Diluted enzyme solution (5 µl) was added to 990 µl of an 
assay mixture containing 50 mM phosphate buffer, pH 7.4, containing 1 mM EDTA and 
100 mM cytochrome c in the presence or absence of inhibitor. Activity was determined 
by measuring the reduction of cytochrome c after addition of 5 µl of 5 mM Q0C10BrH2 
(QH2).  A millimolar extinction coefficient of 18.5 cm−1 mM−1 was used to calculate the 
activity. The bc1 complex used in these experiments had a specific activity about 20 µmol 
cytochrome c reduced/min/nmol cytochrome b. 
Stopped-Flow Experiments 
 For the determination of electron transfer rates between the quinol and heme b or 
heme c1, the cytochrome bc1 complex was mixed with various concentrations of quinol at 
room temperature in an Applied Photophysics stopped-flow reaction analyzer SX.18MV 
(Leatherhead, England). The complex was diluted in the same storage buffer to a 
cytochrome c1 concentration of 100 µM. Quinol was diluted in 0.2% DM and 0.2% OG 
to various concentrations. Reductions of cytochrome b and cytochrome c1 were 
monitored by the increase of absorption at 559 nm and 550 nm, respectively, and 
photodiode array scan between 600-500 nm as well. A set of observed rate constants was 
measured as a function of the concentration of quinol, 1.7-, 3.34-, 6.66-, and 10-fold 
greater than that of the concentration of cytochrome c1. When an inhibitor was used, the 
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cytochrome bc1 complex was treated with 5-fold molar excess of the inhibitor over heme 
c1 for 15 minutes prior to the experiment. 
Freeze-Quenching Experiments 
The cytochrome bc1 complex was diluted in the same storage buffer to a 
cytochrome c1 concentration of 100 µM and mixed at 1:1 ratio with 666 µM QH2 in 0.2% 
DM and 0.2% OG inside the Ultrafast Microfluidic Mixer (Figure 19B). Various time 
points of the mixture, from 100 µs to 5 ms, were freeze quenched at liquid nitrogen 
temperature and packed into EPR tubes (Figure 19A). All EPR tubes were stored in 
liquid nitrogen temperature before analysis (8).  
EPR Experiments 
 The redox state of the ISP, cytochrome b, and c1 were determined by EPR (11), 
using a Bruker EMX Spectrometer at temperature of about 6 K. The instrument settings 
were as follows: microwave frequency, 9.45 GHz; microwave power, 2.15 mW; 
modulation amplitude, 19.57 G; time constant, 0.655 s, and modulation frequency, 100 
KHz. Previous experiments indicated that the air trapped inside the sample causes a 
distorted base line, especially in the heme b/c1 region of the EPR spectrum. To achieve 
high signal sensitive, the air remaining within the sample was eliminated by first dipping 
the EPR tubes containing the freeze-quenched samples into a mixture of isopentane and 
liquid nitrogen. This solution is at a temperature of about -160 °C. Then the EPR tubes 
were subjected to vacuum for 30 seconds before being put into the EPR spectrometer. 























Figure 19. Ultrafast microfluidic mixer and freeze-quenching device for bc1 complex 
reduction by QH2. The cytochrome bc1 complex was diluted in the same storage buffer 
to a cytochrome c1 concentration of 100 µM and mixed at 1:1 ratio with 666 µM QH2 in 
0.2% DM and 0.2% OG inside the Ultrafast Microfluidic Mixer. Various time points of 
the mixture, from 100 µs to 5 ms, were freeze quenched at liquid nitrogen temperature 
and packed into EPR tubes. 
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to valley around g=1.89 (gy), and the amount of reduction of bL was calculated based on 
the integrated peak area at g=3.77. As described in enzyme preparations and assays, 
proxyl was added in as an internal standard. In order to normalize the reduction between 
different time points, both values were divided by the spin label intensity at g=1.98 
before comparison with other samples. 
 
RESULTS AND DISCUSSION 
Observed Rate Constants Between the Quinol and Heme b or Heme c1 
 By using stopped-flow mixing, reductions of cytochrome b and cytochrome c1 in 
bc1 complex by QH2 were monitored by the increase of absorption at 559 nm and 550 
nm, respectively. With varying concentration of QH2, 1.7-, 3.34-, 6.66-, and 10-fold 
greater than that of the concentration of heme c1, a set of observed rate constants were 
obtained for reductions of both heme b and heme c1 (Figure 20A, B, Table IV). As shown 
in Figure 20A, heme b reduction was followed by a slower reoxidation assigned as 
electron transfer from the heme b to ubiquinone at the Qi site of the enzyme. A 50% 
increase of [QH2] from 333 µM to 500 µM only yielded a 6% increase in the rate 
constant of heme b, from 407 s-1 to 432 s-1. Similar results were for the rate constants of 
heme c1 reduction as well (Figure 20B), a 50% increase of [QH2] from 333 mM to 500 
mM only gave a 12% increase for the rate constants, from 167 s-1 to 187 s-1. These results 
indicated that the reaction was close to its maximum rate due to the limited quinol 





Figure 20. Electron transfer rates between the quinol and heme b or heme c1. Fully 
oxidized cytochrome bc1 complex was diluted in 50 mM Tris-Cl, pH 8.0, containing 
0.01% DM and 0.33 M sucrose to a concentration of cytochrome c1 of 100 µM. QH2 was 
diluted in 0.2% DM and 0.2% OG to 167 µM, 333 µM, 667 µM, and 1 mM. The 
complex and QH2 were mixed 1:1 in stopped-flow apparatus, which gives a final 
concentration of  cytochrome c1 of 50 µM and QH2 of 84, 167, 333, and 500 µM. 
Reductions of cytochrome b (A) and cytochrome c1 (B) were followed by measuring the 




Table IV. Electron transfer rate constants between QH2 and cytochrome b/c1.  
                  Rate Constant 
[QH2] QH2  cyt. b QH2  cyt. c1
84 µM 224/sec 87/sec 
167 µM 300/sec 100/sec 
333 µM 407/sec 167/sec 
500 µM 432/sec 187/sec 
 
90
solution. The t1/2=1.6 ms was calculated with the maximum observed rate constant of 432 
s-1 for heme b reduction, or electron transfer from QH2 to heme b at the Qo site. Also 
t1/2=3.7 ms was calculated with the maximum observed rate constant of 187 s-1 for heme 
c1 reduction, or electron transfer from QH2 to heme c1. 
 Figure 21 shows the photodiode array scanning of bc1 complex reduction by QH2. 
Fully oxidized cytochrome bc1 complex was diluted in 50 mM Tris-Cl, pH 8.0, 
containing 0.01% DM and 0.33 M sucrose to a concentration of cytochrome c1 of 100 
µM. QH2 was diluted in 0.2% DM and 0.2% OG to 667 µM. The complex and QH2 were 
mixed 1:1 in stopped-flow apparatus, which gave a final concentration of cytochrome c1 
of 50 µM and QH2 of 333 µM. The reaction was followed by photodiode array scanning 
for 10 seconds. The final after mixing concentration of heme c1 was 50 µM, and QH2 was 
333 µM. The reaction showed the early reduction of heme b, started before 1 ms and 
followed by the reduction of heme c1, which started after 3 ms. This was consistent with 
the measurement of rate constants, which showed the electrons transfer from QH2 to 
heme b was nearly 2.5 fold (407 s-1/167 s-1) faster than from QH2 to heme c1 under the 
same mixing condition and QH2 concentration. 
 When Qi site inhibitor antimycin A was added to the bc1 complex prior to the 
stopped-flow experiments (Figure 22), an initial rise in absorbance corresponding to 
heme b reduction was followed by much slower reduction of heme c1 when comparing 
with the reaction without antimycin A. Antimycin A blocks the electron transfer from 
heme bH to quinone or semiquinone at the Qi site. During the transient state of the 
reaction, the accumulation of reduced heme b slowed down the electron transfer from ISP 
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Figure 21. Transient state electron transfer between the quinol and bc1 complex. 
Fully oxidized cytochrome bc1 complex was diluted in 50 mM Tris-Cl, pH 8.0, 
containing 0.01% DM and 0.33 M sucrose to a concentration of cytochrome c1 of 100 
µM. QH2 was diluted in 0.2% DM and 0.2% OG to 667 µM. The complex and QH2 were 
mixed 1:1 in stopped-flow apparatus, which gives a final concentration of cytochrome c1 
of 50 µM and QH2 of 333 µM. The reaction was followed by photodiode array scanning 
for 10 seconds. 
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Figure 22. Transient state electron transfer between the quinol and bc1 complex in 
the presence of antimycin A. Fully oxidized cytochrome bc1 complex was diluted in 50 
mM Tris-Cl, pH 8.0, containing 0.01% DM and 0.33 M sucrose to a concentration of 
cytochrome c1 of 100 µM. QH2 was diluted in 0.2% DM and 0.2% OG to 667 µM. 
Antimycin A was added to the bc1 complex to a final concentration of 500 µM, and 
incubated for 10 minutes. The complex and QH2 were mixed 1:1 in stopped-flow 
apparatus, which gives a final concentration of cytochrome c1 of 50 µM and QH2 of 333 




to heme c1 at the Qo site which implies the possible requirement of an electron 
equilibrium between the two heme b (bL and bH) and the quinone in order to facilitate the 
movement of reduced [2Fe-2S] towards heme c1. A study of the effects of antimycin on 
the pre-steady state reduction kinetics of the bc1 complex, in the presence or absence of 
endogenous ubiquinone, shown similar results. In the presence of quinone, antimycin 
slowed the rate of heme c1 reduction by ~10 fold, while a slower heme c1 reduction was 
also observed in the absence of endogenous quinone, similar to that in the presence of 
quinone plus antimycin. This suggests that both the low potential and high potential 
redox components control quinol oxidation at the Qo site (12). 
 In the presence of stigmatellin, a Qo site inhibitor, which allows reduction of the 
ISP and locks the ISP in the conformation close to cytochrome b (4,13), total inhibition 
of heme c1 reduction occurred (Figure 23), while the reduction of heme b continued 
through the electron transfer between heme bH and quinol or semiquinone at the Qi site. 
When both stigmatellin and antimycin A were added to the bc1 complex together (Figure 
24), which blocks both electron transfer at Qo and Qi sites, an almost total inhibition of 
heme b and heme c1 reduction was observed.  
Freeze-Quenching of bc1 Complex Reduced by QH2 
 As shown in Figure 19, the bc1 complex was diluted in the same storage buffer to 
a cytochrome c1 concentration of 100 µM and mixed at 1:1 ratio with 666 µM QH2 in 
0.2% DM and 0.2% OG inside the mixer. At various time points of the mixture, from 100 
µs to 5 ms, were freeze quenched and ground to powder by the two copper wheels at 
liquid nitrogen temperature and packed into EPR tubes (8). 
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Figure 23. Transient state electron transfer between the quinol and bc1 complex in 
the presence of stigmatellin. Fully oxidized cytochrome bc1 complex was diluted in 50 
mM Tris-Cl, pH 8.0, containing 0.01% DM and 0.33 M sucrose to a concentration of 
cytochrome c1 of 100 µM. QH2 was diluted in 0.2% DM and 0.2% OG to 667 µM. 
Stigmatellin was added to the bc1 complex to a final concentration of 500 µM, and 
incubated for 10 minutes. The complex and QH2 were mixed 1:1 in stopped-flow 
apparatus, which gives a final concentration of cytochrome c1 of 50 µM and QH2 of 333 
µM. The reaction was followed by diode array scanning for 10 seconds. 
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Figure 24. Transient state electron transfer between the quinol and bc1 complex in 
the presence of both antimycin A and stigmatellin. Fully oxidized cytochrome bc1 
complex was diluted in 50 mM Tris-Cl, pH 8.0, containing 0.01% DM and 0.33 M 
sucrose to a concentration of cytochrome c1 of 100 µM. QH2 was diluted in 0.2% DM 
and 0.2% OG to 667 µM. Antimycin A and stigmatellin were added to the bc1 complex to 
a final concentration of 500 µM each, and incubated for 10 minutes. The complex and 
QH2 were mixed 1:1 in stopped-flow apparatus, which gives a final concentration of 
cytochrome c1 of 50 µM and QH2 of 333 µM. The reaction was followed by diode array 
scanning for 10 seconds. 
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Measurements of ISP and Heme b/c1 Reduction by EPR 
 As shown in Figure 25, a fully oxidized bc1 complex EPR spectrum (A) shows the 
signal of heme bL (g=3.76) and heme bH/c1 (g=3.49), while a fully reduced bc1 complex 
EPR spectrum (B) shows characteristic features of ISP with gx=1.80, gy=1.89, and 
gz=2.02. In Figure 26A, a partially reduced bc1 complex EPR spectrum shows 
characteristic features of ISP in the presence of proxyl, with signal of gx, y, z=1.98, 2.00, 
and 2.02 are all from the proxyl. A fully oxidized ISP spectrum under the same condition 
shows a flat line at the gy=1.89 position. Figure 26B shows the EPR spectrum with only 
proxyl under the same buffer condition, which is identical to a fully oxidize bc1 complex 
spectrum. 
 The amount of ISP reduction was calculated based on the absolute value of peak 
to valley intensity around g=1.89, then divided by the absolute value of the “dip” 
amplitude of g=1.98 from proxyl in order to normalize the value between different time 
points samples. By comparing with the fully reduced ISP sample, whose reduction of ISP 
was calculated the same way, we were be able to calculate the percentage reduction of 
ISP at different time points.  
 A similar approach was adopted for calculating the percentage reduction of heme 
bL by using the absolute value of the peak high at g=3.76, then normalized by the 
absolute value of the “dip” amplitude at g=1.98 from proxyl. By comparing with the fully 


















Figure 25. EPR spectra of cytochrome bL, cytochrome bH/c1 (A) and ISP (B) and their g 
values. The instrument settings were as follows: microwave frequency, 9.45 GHz; 
microwave power, 2.15 mW; modulation amplitude, 19.57 G; time constant, 0.655 s, and 












Figure 26. EPR spectra of ISP with spin label (proxyl). A) A partially reduced bc1 
complex EPR spectrum. B) A EPR spectrum with only proxyl under the same buffer 
condition, which is identical to a fully oxidize bc1 complex EPR spectrum. The 
instrument settings were as follows: microwave frequency, 9.45 GHz; microwave power, 
2.15 mW; modulation amplitude, 19.57 G; time constant, 0.655 s, and modulation 
frequency, 100 KHz.
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 In Figure 27, the ISP and heme bL reduction percentage are colored in red (circle) 
and blue (dot), respectively, and plotted as functions of time in a double y axes manner. 
Notice the zero time point was based on a control sample prepared under the same 
condition in the absence of QH2. The reduction of both redox centers reached around 11-
12% within 1 ms. The first phase reduction of ISP started at between 100 to 200 µs with 
t1/2 of 250 µs, while reduction of heme bL starts around the same time with t1/2 of 300 µs. 
The rate constant for electron transfer from quinol to ISP at Qo site was calculated at 
2772 s-1, and 2310 s-1 for electron transfer from quinol to heme bL.  
 Because the rate constants are so large, kinetic characterization of the electron 
transfer reactions involving bc1 complex has proven to be difficult. Using a light flash to 
initiate the electron transfer cycle, a 1650 s 1 rate constant was reported  for electron 
transfer from quinol to ISP at the Qo site in R. capsulatus bc1 complex (14). A rate 
constant of 1200 s 1 was found by using a binuclear ruthenium complex to rapidly 
photooxidize cytochrome c1 in R. sphaeroides bc1 complex (15). Also using the same 
technique of rapid photoreduce/photooxidize cytochrome c1 with ruthenium dimer 
(Ru2D), oxidant-induced reduction of cytochrome bH was observed at a rate constant of 
250 s-1 in the presence of antimycin A with bovine bc1 complex, and 1000 s 1 with 
R. sphaeroides bc1 complex (15). The rate constant for electron to transfer from quinol to 
heme bs was found to be 270 s 1 using a photoreleasable quinol substrate with 
mitochondrial cytochrome bc1 (16).  
 Thus, the rate constants found in this study are significantly higher than in the 
previous work. The slightly slower rate constant for electron transfer from quinol to heme 
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Figure 27. ISP (in red circle) and heme bL (in blue dot) reduction percentage by QH2, 
calculated from EPR spectra, at time points between r 0 to 1 ms. 
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bL than that to ISP, indicates the first electron is transferred to the thermodynamically 
favored ISP, then the second electron is transfer to heme bL, which is consistent with the 
Q-cycle mechanism. Also the observation of nearly simultaneous reduction of both ISP 
and cytochrome bL strongly supports the electron transfer bifurcation at the Qo site, 
which is the heart to the operation of the Q-cycle mechanism.  
Possible Detection of Semiquinone Radical at the Qo Site 
 After the first electron transfer from quinol to ISP at the Qo site, a semiquinone is 
formed, which carries a negative charge and an unpaired electron detectable by EPR. Due 
to its subsequent fast electron transfer to heme bL, measurement of semiquinone at the Qo 
site in a steady state reaction can’t be successful. Attempts were made to detect the 
semiquinone at Qo site under the condition of oxidant-induced reduction of heme b in the 
presence of antimycin A, in which both heme b are reduced and cytochrome c1 is 
oxidized (17). A semiquinone signal was found that was sensitive to BAL (an inactivator 
of the iron-sulfur center (18)) and which was hence considered to a semiquinone in the 
Qo site. Later though, the signal was proven to be due to semiquinones of complexes I 
and II (19). 
 Using this ultrafast freeze-quenching technique, it is possible for us to detect the 
existent of semiquinone in the Qo site as the observation of the reduction of both ISP and 
heme b starts after 100 µs, which is longer than the dead time of the instrument, which is 
75 µs.  
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 As the semiquinone give a single peak at g=2.00 in EPR spectrum, it will overlap 
with the gy peak of proxyl as well. A sharp increase of the ratio between the intensity of 
g=2.00 and g=1.98 would indicate the presence of the semiquinone. As shown in Figure 
28, the percentage increase of such value is plotted against time. The time points at 400 
µs and 700 µs show 20% and 17% increase of the g=2.00 intensity, while the rest of the 
samples show a increase average about 6%. This might suggest the possible detection of 
semiquinone in the Qo site. Further experiments will be necessary to carry out by testing 
samples at the same time points, and at the absence of proxyl to minimize the effect from 




Figure 28. Percentage increase of the ratio between the intensity of g=2.00 and 







1. Mitchell, P. (1976) J Theor Biol 62, 327-367 
2. Trumpower, B. L. (1990) J Biol Chem 265, 11409-11412 
3. Xia, D., Yu, C. A., Kim, H., Xia, J. Z., Kachurin, A. M., Zhang, L., Yu, L., and 
Deisenhofer, J. (1997) Science 277, 60-66 
4. Zhang, Z., Huang, L., Shulmeister, V. M., Chi, Y. I., Kim, K. K., Hung, L. W., 
Crofts, A. R., Berry, E. A., and Kim, S. H. (1998) Nature 392, 677-684 
5. Iwata, S., Lee, J. W., Okada, K., Lee, J. K., Iwata, M., Rasmussen, B., Link, T. 
A., Ramaswamy, S., and Jap, B. K. (1998) Science 281, 64-71 
6. Tian, H., Yu, L., Mather, M. W., and Yu, C. A. (1998) J Biol Chem 273, 27953-
27959 
7. Tian, H., White, S., Yu, L., and Yu, C. A. (1999) J Biol Chem 274, 7146-7152 
8. Lin, Y., Gerfen, G. J., Rousseau, D. L., and Yeh, S. R. (2003) Anal Chem 75, 
5381-5386 
9. Yu, C. A., and Yu, L. (1982) Biochemistry 21, 4096-4101 
10. Yu, C. A., and Yu, L. (1980) Biochim Biophys Acta 591, 409-420 
11. McCurley, J. P., Miki, T., Yu, L., and Yu, C. A. (1990) Biochim Biophys Acta 
1020, 176-186 
12. Snyder, C. H., Gutierrez-Cirlos, E. B., and Trumpower, B. L. (2000) J Biol Chem 
275, 13535-13541 
13. Hunte, C., Koepke, J., Lange, C., Rossmanith, T., and Michel, H. (2000) Structure 
Fold Des 8, 669-684 
14. Crofts, A. R., and Wang, Z. (1989) Photosynth. Res. 22, 69-87 
15. Sadoski, R. C., Engstrom, G., Tian, H., Zhang, L., Yu, C. A., Yu, L., Durham, B., 
and Millett, F. (2000) Biochemistry 39, 4231-4236 
16. Hansen, K. C., Schultz, B. E., Wang, G., and Chan, S. I. (2000) Biochim Biophys 
Acta 1456, 121-137 
17. de Vries, S., Albracht, S. P., Berden, J. A., and Slater, E. C. (1981) J Biol Chem 
256, 11996-11998 
18. Slater, E. C., and de Vries, S. (1980) Nature 288, 717-718 






Candidate for Degree of  
Doctor of Philosophy 
Thesis: STRUCTURE-FUNCTION STUDIES OF ELECTRON TRANSFER COMPLEXES 
 IN BOVINE HEART MITOCHONDRIA 
 
Major Field: Biochemistry and Molecular Biology 
Biographical: 
Personal Data: Born in Wuhan, Hubei Province, People’s Republic of China, 1971, 
the son of Lingpin Shen and Weiwen Zhu. 
 
 Education: Graduated from Guangzhou No. 6 Middle School, Guangzhou, 
 Guangdong, P. R.  China in June 1990; received Bachelor of Science degree 
 from Zhongshan (Sun Yat-Sen) University, Guangzhou, Guangdong, P. R. 
 China in June1994. Completed the requirements for the Doctor of Philosophy 
 degree with a major in Biochemistry and Molecular Biology at Oklahoma 
 State University in December, 2004. 
  
Abstracts Presented at Meetings: Identification of Heme-Ligating Residues in the Largest 
Membrane-Anchoring Subunit (QPs1) of Bovine Heart Mitochondrial 
Succinate:Ubiquinone Reductase. (2001) Biophysical Journal, 188, B 44. Fast 
Kinetic Studies of Mitochondrial Cytochrome bc1 Complex. (2005) Biophysical 
Journal. 
 
Publications:  Reconstitution of Cytochrome b-560 (QPs1) of Bovine Heart Mitochondrial 
 Succinate-Ubiquinone Reductase. Biochim. Biophys. Acta, 1363, 35-46. Expression 
 of GST-EGF Fusion Protein in E. coli and Its Purification. Acta Scientiarum 
 Naturalium University Sunyatsen, 37 (3), 13-16. A Mathematical Model for the 
 Transport of Drug Infused in Subcutaneous Tissue. The Fouth China-Japan-USA-
 Singapore Conference on Biomechanics, 211-213. 
 
Professional Memberships: Biophysical Society; American Association for the Advancement 
 of Science; Oklahoma Academy of Science. 
Name: Jian Zhu            Date of Degree: December, 2004 
Institution: Oklahoma State University           Location: Stillwater, Oklahoma 
Title of Study:  STRUCTURE-FUNCTION STUDIES OF ELECTRON 
   TRANSFER COMPLEXES IN BOVINE HEART 
   MITOCHONDRIA 
 
Page in Study: 107      Candidate for the Degree of Doctor of Philosophy 
 
Major Field: Biochemistry and Molecular Biology 
 
 Various complexes within the bovine heart mitochondrial electron transfer chain 
were studied. The QPs1 subunit of Succinate:Ubiquinone Reductase was over expressed 
in Escherichia coli DH5α cells as a glutathione S-transferase fusion protein (GST-QPs1) 
using the expression vector, pGEX/QPs1. Recombinant QPs1 contains little cytochrome 
b560 heme. However, addition of hemin chloride reconstitutes the spectral characteristics 
of cytochrome b560. Reconstituted cytochrome b560 in recombinant QPs1 shows a EPR 
signal at g=2.91. Histidine residues at positions 98 and 120 are responsible for the heme 
ligation because the H98D or H120D-reconstituted QPs1 fail to restore cytochrome b560 
upon addition of hemin chloride. 
 
 A purification procedure for NADH dehydrogenase of NADH:Ubiquinone 
Reductase was developed. This procedure involves acid extraction in the presence of 
organic solvent followed by ammonium sulfate fractionation, and DEAE column 
chromatography. Purified NADH dehydrogenase contains 3 protein subunits with 
apparent molecular weight of 51, 24, and 10 kD. It catalyzes oxidation of NADH by 
artificial electron acceptor, ferricyanide, with specific activity of 471 µmol Fe(CN)63- 
reduced/min/mg protein. The purified NADH dehydrogenase contains one FMN, five 
irons, and two EPR detectable iron sulfur clusters, one [4Fe-4S] and one [2Fe-2S]. 
Preliminary results of crystallization have been discussed.  
 
 Using ultra-fast microfluidic mixer and freeze-quenching device, coupled with 
EPR, the pre-steady state kinetic of ISP reduction by ubiquinol was determined. The 
complex was mixed with reduced Q0C10Br (QH2) to a final concentration of 50 µM of 
cytochrome c1, and 333 µM of QH2 in the ultrafast microfluidic mixer and freeze-
quenching at various time points, ranging from 100 µs to 5 ms. The first phase 
reduction of ISP starts between 100 to200 µs with t1/2 of 250 µs. A similar reduction 
kinetic is also observed for cytochrome bL with t1/2 µs of 350 µs indicating an almost 
simultaneously reduction of both ISP and bL. Possible detection of semiquinone 
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